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2.1 The endothelium 
The endothelium is a thin monolayer of cells which line the lumen of all blood vessels, 
thereby regulating exchanges between the blood and the surrounding tissue. Endothelial cells 
(ECs) are not inert but rather have metabolic and secreting functions. Moreover, ECs exert 
significant autocrine, paracrine, and endocrine actions and influence either smooth muscle 
cells, platelets or peripheral leukocytes.1, 2 
The endothelium plays an important role in many physiological functions including: the 
control of vascular tone, blood cell trafficking, hemostatic balance, permeability, 
inflammation and host defense as well as the formation of new blood vessels (angiogenesis). 
The loss of proper endothelial function, also referred to as endothelial dysfunction, has been 
associated with a number of pathological processes that are briefly discussed below.3, 4 
i.Disturbed endothelial function plays a prominent role in cardiovascular diseases. As the 
major cause of death in the USA and Europe, cardiovascular diseases are characterized 
by multiple factors including impaired vasodilation, tissue perfusion, homeostasis, and 
thrombosis. One of the main mechanisms of a variety of cardiovascular pathological 
processes, like hypertension and atherosclerosis, is associated with a reduced nitric 
oxide (NO) bioavailability.5-9 
ii. Endothelial cells can be the prime target for an infection leading to severe 
inflammation. As a first line of defense, ECs, besides monocytes and macrophages, 
recognize invading pathogens. These cells are able to produce different cytokines, 
adhesion molecules, and enzymes (such as matrix metalloproteinases or NO synthase) 
and react to a variety of mediator substances, thereby modulating inflammatory 
processes.10, 11 
iii.ECs are a target for tumor-induced blood vessel growth (angiogenesis), a process 
leading to dissemination and implantation of tumor cells, finally leading to metastasis. 
With the identification of several pro-angiogenic molecules (such as growth factors and 
the angiopoietins) and anti-angiogenic substances (such as platelet factor-4 and 
angiostatin), it is recognized that therapeutic interference with vasculature formation 
offers a tool for clinical applications in various pathological situations. 
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In addition to the abovementioned diseases, there are numerous other pathopysiological states 
caused via disturbed endothelial function. Therefore, the regulation of endothelial processes 
represents a valid approach for drug discovery in order to combat these severe disorders. In 
brief, the endothelium offers enormous, yet largely untapped diagnostic and therapeutic 
potential. 
2.2 Ginkgo biloba extract - EGb 761 
Ginkgo biloba (“maidenhair tree” in English, “Ginkgobaum” in German) has been described 
as a “living fossil” that represents the only surviving species of the order Ginkgoales. The use 
of Ginkgo biloba fruits for medical purposes dates back to the origins of Traditional Chinese 
Medicine. However in Europe, the extract of Ginkgo biloba leaves was first introduced into 
medical practice in 1965 by Dr. Willmar Schwabe (Karlsruhe), a German physician and 
pharmacist. Since that time, the Ginkgo biloba leaf extract EGb 761 has been developed and 
has become commercially available as drops and tablets under the trade-name Tebonin® (Dr. 
Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany). EGb 761 is a water/acetone extract 
that has been stringently standardized to ensure the consistency of its composition and reliable 
safety and efficacy profiles. The standard is a ratio of 35-67:1 (dried Ginkgo biloba leaves to 
final extract) containing approximately 24% flavonoid glycosides (Figure 2.1), 6% terpene 
trilactones, 7% proanthocyanidins and certain low molecular weight organic acids.12, 13 
Terpene trilactones are unique to Ginkgo biloba and can be divided into different subgroups: 
ginkgolides A, B, C, and J (diterpenoids, Figure 2.2) as well as the bilobalide (sesquiterpene, 
Figure 2.3). Moreover, EGb 761 is standardized to contain less than 5 ppm ginkgolic acids 
(Figure 2.4) as these substances can cause allergic reactions, especially dermatitis.14 
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Figure 2.1 Chemical structure of flavonoids in EGb 761. 
The 24% flavonoids present in EGb 761 are nearly exclusively flavonol-O-glycosides; i.e., 
combinations of the phenolic aglycon (kaempherol, quercetin, myricetin or isorhamnetin) with 
sugars which can be either glucose and/or rhamnose. 
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Figure 2.2 Chemical structure of ginkgolides in EGb 761. 
The ginkgolides A, B, C and J are displayed. Taken together ginkgolides A, B and C account 
for 3.1% of EGb 761. In contrast the ginkgolide J accounts for only ≤0.5%. 
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Figure 2.3 Chemical structure of the bilobalide in EGb 761. 
The bilobalide is a sesquiterpen, which accounts for about 2.9% of EGb 761. 
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Figure 2.4 Chemical structure of ginkgolic acids in Ginkgo biloba leaves and fruits. 
Ginkgolic acids are chemicals classified as alkylphenols that can cause allergic skin 
inflammation. Because of this and other undesired side effects, the maximum level of ginkgolic 
acids in the standardized extract EGb 761 is restricted to an amount of less than 5 ppm. 
 
Current therapeutic strategies 
Today, preparations of EGb 761 are among the most widely used herbal remedies in the 
industrialized world. Since 1995 the extract of Ginkgo biloba leaves holds a top-selling 
position in the USA. Clinical studies conducted during the last 30 years have revealed that 
EGb 761 is useful in treating a wide range of diseases including:12, 15, 16 
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i. Disturbances of brain function: EGb 761 exerts cognition-enhancing effects, and is 
therefore commonly used in treatment of symptoms associated with both cognitive 
decline and more severe types of senile dementias of primary degenerative nature, 
such as Alzheimer’s disease, and vascular dementia and mixed types.17-19 
ii. Peripheral arterial disease: EGb 761 improves the pain-free walking distance in 
Fontaine’s Stage II intermittent claudication (peripheral arterial occlusive disease, 
pAOD), a condition characterized by pain in the legs while walking, indicating tissue 
ischemia.20-22 
iii. Dizziness and tinnitus of a vascular and involutional origin.23 
 
Therapeutic actions 
Different molecular mechanisms of action can be used to explain the therapeutic effects of 
EGb 761. This may be due to the various active chemical constituents, which act in a 
complementary manner. Along this line, additive, antagonistic, and synergistic effects may 
occur in pharmacological experiments as a result of interactions of the different active 
compounds. This combined activity, or polyvalent action, is responsible for the therapeutic 
benefits and is discussed very briefly below.12, 15, 16 An overview of the pharmacological 
effects of EGb 761 according to the German Federal Health Authority (BGA-Commission E, 
1994) is given in Table 2.1.24 
i. EGb 761 has vasoregulatory effects. Studies conducted during the past three decades 
have revealed that several molecular mechanisms contribute to the vasoregulatory 
activity of EGb 761. The extract elicits a vasorelaxant effect that partly depends on an 
intact endothelium. Furthermore, EGb 761 has beneficial effects on the rheological 
properties of the blood, defined as increased fluidity and inhibition of platelet and 
erythrocyte aggregation. These effects increase the blood supply in the brain and other 
body organs, thereby improving their oxygen and nutrient supply.25, 26 
ii. EGb 761 exerts a “stress-alleviating” action. Several rodent models on defined animal 
behavior revealed the anti-stress activity of EGb 761 that can be considered being 
anxiolytic and/or antidepressant. Furthermore, the extract partially antagonizes stress-
responses via reduction of adrenal glucocorticoid synthesis.27, 28 
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iii. EGb 761 exerts antioxidant and free radical scavenging activities. Numerous studies 
have shown that EGb 761 can oppose the deleterious effects of oxidative damage 
caused by free radicals and related ROS. EGb 761 thereby acts directly via scavenging 
free radicals or indirectly via either decreasing the formation of free radicals or 
enhancing the expression of genes that encode antioxidant enzymes.29, 30 
iv. EGb 761 has neuroprotective properties and effects on learning, memory and 
behavior. The neuroprotective action of EGb 761 can be summarized as being the 
result of improved cerebral energy metabolism, protection against hypoxia and 
ischemia, decreasing ROS-induced brain damage, preventing brain edema, preserving 
mitochondrial function, and influences on central cholinergic systems known to be 
involved in learning and memory.31, 32 
v. EGb 761 has gene-regulatory effects. cDNA microarray analyses have shown that 
exposure of human bladder cancer cells to EGb 761 produced an adaptive 
transcriptional response and an altered the expression of several genes involved in 
regulating cell proliferation and apoptosis. These results provide a first hint why most 
of the clinically beneficial effects require repeated administration.33 
Table 2.1 Pharmacological effects of EGb 761 
− Improvement of hypoxic tolerance, particularly in the cerebral tissue. 
− Inhibition of the development of traumatically or toxically induced cerebral edema, and 
acceleration of its regression. 
− Reduction in retinal edema and cellular lesions in the retina. 
− Inhibition in age-related reduction of muscarinergic cholinoceptors and alpha-
adrenoceptors as well as stimulation of choline uptake in the hippocampus. 
− Increased memory performance and learning capacity, improvement in the compensation 
of disturbed equilibrium, improvement of blood flow. 
− Improvement of rheological properties of the blood. 
− Antagonism of the platelet-activating factor (PAF) (ginkgolides). 
− Inactivation of toxic oxygen radicals (flavonoids). 
− Improvement of mitochondrial function (ATP production). 
− Neuroprotective effect (ginkgolides A and B, bilobalide). 
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2.3 Aim of the study 
In recent years, the interest in traditional herbal remedies has grown rapidly in the 
industrialized world. Despite the knowledge about its properties and current therapeutic 
applications, there is an increasing need for understanding the molecular mechanisms and 
signaling pathways. Therefore, aim of the present study was to investigate the influence of the 
standardized Ginkgo biloba extract EGb 761 on signaling pathways in endothelial cells.  
For this purpose, two different projects were pursued: 
1) Effects of EGb 761 on endothelial nitric oxide synthase (eNOS) both in cultivated human 
endothelial cells and in in vivo systems: 
Cardiovascular diseases are the major cause of death in the USA and Europe. Moreover, a 
variety of pathological processes, including hypertension and atherosclerosis, are associated 
with endothelial dysfunction involving a reduced nitric oxide (NO) bioavailability. Although 
the efficacy of the standardized Ginkgo biloba extract has been well proven, the underlying 
molecular mechanisms and signaling pathways leading to Ginkgo’s beneficial cardiovascular 
effects have as yet remained widely unknown. Thus, aim of the study was to elucidate the 
molecular basis on which EGb 761 might protect against endothelial dysfunction in vitro and 
in vivo. We hypothesized that EGb 761 is able to influence the nitric oxide formation in 
endothelial cells. 
2) Effects of EGb 761 on angiogenic parameters in endothelial cells: 
Angiogenesis, the formation of new blood vessels by sprouting from pre-existing capillaries, 
is a pre-requisite for tumor development and metastasis. Inhibition of angiogenesis, therefore, 
represents a valid approach for cancer treatment or even prevention and is successfully used 
in clinical applications. The standardized Ginkgo biloba extract EGb 761 is traditionally used 
for anticancer treatment.13 However, as seen with most of the widely used herbal remedies, no 
profound mechanistic studies providing a rational, mechanistic molecular background for the 
respective therapeutic indications exist. Thus, aim of the study was to provide a rational basis 
elucidating EGb 761 protective effects on angiogenic parameters in endothelial cells. Along 
this line, we aimed to clarify the influence of EGb 761 on growth factor-signaling pathways in 
endothelial cells focusing on the ERK-cascade and the role of phosphatases. 
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2.4 Endothelial nitric oxide production 
In 1980 Furchgott and Zawadzki provided the landmark observation that endothelial cells 
produce a factor that causes relaxation of the underlying vascular smooth muscle cells.34 
Seven years later this factor, called the endothelium-derived relaxing factor (EDRF), was 
shown to be identical to the free diffusible gas nitric oxide (NO).35, 36 NO, a simple diatomic 
molecule is crucial for maintaining vascular endothelial health and function. In detail, NO is 
released by endothelial cells and is a major endogenous vasodilator counterbalancing 
vasoconstriction. It participates as key mediator in the signaling pathway  
L-arginine/NO/cyclic guanosine monophosphate (cGMP) as displayed in Figure 2.5. 
CaM
L-arginineCav-1
GTP cGMP PKG
HSP 90
smooth muscle fibers
sGC
P
eNOS
NO
vasodilatation
endothelial cell
L-citrulline
 
Figure 2.5 The L-arginine/NO/cyclic GMP pathway leading to vasodilation. 
This signaling cascade starts with the activation of the endothelial nitric oxide synthase (eNOS) 
in response to receptor-dependent agonists or physicochemical stimuli. The enzyme eNOS 
generates NO and L-citrulline from L-arginine and oxygen. NO diffuses to the adjacent smooth 
muscle where it interacts with soluble guanylate cyclase (sGC) leading to an increase in cyclic 
guanosine monophosphate (cGMP) formation. cGMP elicits different biological effects 
including vasodilation by activation of cGMP-activated protein kinase (protein kinase G, 
PKG). 
In the endothelium, NO synthesis is controlled by the endothelial form of nitric oxide 
synthases (NOSs, see section 2.4.2 for detailed description). The small, lipophilic gas NO 
rapidly diffuses out of the endothelial cells into neighboring smooth muscle cells. In the 
adjacent smooth muscle NO activates the soluble guanylate cyclase (sGC) by binding of iron 
in the active site, thereby stimulating the production of the small intracellular mediator 
cGMP. Once produced, cGMP elicits different biological functions including smooth muscle 
relaxation through the activation of cGMP-dependent protein kinase (protein kinase G, PKG), 
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thus dilating the vessel and increasing blood flow. The current chapter summarizes the 
physiological and pathophysiological role of NO in the endothelium, the cellular regulation of 
NOS isoforms and gives a short overview about the PI3K/Akt signaling pathway. 
2.4.1 Role of NO in the vascular wall 
In addition to its vasodilator properties, endothelial NO has numerous vasoprotective and 
even anti-atherosclerotic effects. The physiological actions of NO include thrombosis 
protection by inhibition of platelet aggregation and conclusively platelet adhesion to the 
vessel wall. NO mediates the reduction in endothelial permeability as well as the inhibition of 
the expression of the chemoattractant protein MCP-1 and surface adhesion molecules like  
P-selectin and intercellular adhesion molecule-1 (ICAM-1). Furthermore, NO has been shown 
to inhibit DNA synthesis and, in higher concentrations prevent smooth muscle cell 
proliferation and migration. It also exerts anti-inflammatory actions and down-regulates the 
oxidation of low-density lipoproteins (LDLs). Conditions with an absolute or relative NO 
deficit known as endothelial dysfunction, initiate and accelerate the process of atherosclerosis. 
Altogether there are four principle causes of diminished NO bio-activity: (I) decreased 
expression and/or activity of endothelial NO synthase (eNOS), (II) eNOS uncoupling, (III) 
enhanced scavenging of NO and (IV) impaired transmission of NO-mediated signaling events 
(failure of effector mechanisms).37, 38 In fact, eNOS uncoupling, which is the transformation 
of eNOS from a protective enzyme to a contributor of oxidative stress, is likely to play an 
important role in the pathological states. Based on these facts, the enhancement of endothelial 
NO production in an aging or diseased endothelium either by eNOS activation/expression or 
restoring eNOS functionality is of great therapeutic interest.9, 39, 40 
2.4.2 Nitric oxide synthases 
The biological synthesis of NO from the amino acid L-arginine is catalyzed by a family of 
nitric oxide synthases (NOSs). It can be found in three distinct isoforms: (i) neuronal NOS 
(also known as Type I, nNOS or NOS-1) being the isoform first found in neuronal tissue, (ii) 
inducible NOS (also known as Type II, iNOS or NOS-2) being the isoform which is inducible 
in a wide range of cells and tissues, and (iii) endothelial NOS (also denoted as Type III, eNOS 
or NOS-3) being the isoform first found in endothelial cells. These three mammalian NOS 
isoforms can also be differentiated on the basis of their constitutive (nNOS and eNOS) or 
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inducible (iNOS) expression, and their calcium-dependence (nNOS and eNOS) or -
independence (iNOS). All NOS isoforms exhibit a bidomain structure composed of an 
oxygenase and reductase domain, which are linked by a calmodulin (CaM)-recognition site. 
In addition, all three isoforms are hemoproteins and require the following co-factors: the 
reduced nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide 
(FAD), flavin mononucleotide (FMN), and (6R)-5,6,7,8-tetrahydro-L-biopterin (BH4), one of 
the most potent naturally occurring reducing agents. The dimerized enzymes transfer 
electrons from NADPH via FAD and FMN in the reductase domain of one monomer to the 
heme iron (Heme-Fe) in the oxygenase domain of a separate monomer (Figure 2.6). To 
synthesize NO, the enzymes catalyze two successive oxidation-reduction reactions. In the first 
step, NOS hydroxylates L-arginine to N-hydroxy-L-arginine. In the second step, NOS 
oxidizes N-hydroxy-L-arginine generating L-citrulline and NO as final products.41, 42 
 
L-arginine + O2
FMN
FAD
NADPH
Heme-Fe
L-arginine + O2
L-citrulline + NO
−COO-
+H3N−
FMN
FAD
NADPH
Heme-Fe
-OOC−
−NH3+
L-citrulline + NO
 
Figure 2.6 Structure of the eNOS homodimer. 
The enzyme is composed of two identical monomers, and each monomer contains a carboxy-
terminal reductase (dark blue unit) and an amino-terminal oxygenase (light blue unit) domain. 
The electron flow in the eNOS dimer goes via NADPH → FAD → FMN in the reductase 
domain of one monomer to the heme iron in the oxygenase domain of a separate monomer. 
There the reaction of L-arginine with oxygen is catalyzed generating L-citrulline and NO as 
products. The arrows indicate the direction of the electron flow. 
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Endothelial nitric oxide synthase (eNOS) 
In the vasculature, the endothelial NOS is the predominant and most important isoform and is 
responsible for most of the NO produced in this tissue. The eNOS synthesizes NO in a 
Ca2+/calmodulin (CaM)-activated manner in response to a variety of mechanical forces and 
humoral factors. Moreover, to cope with the continuously changing environment, endothelial 
cells need to control their nitric oxide production by various mechanisms. Hence, the enzyme 
eNOS is under complex and tight control, which is afforded by three specific processes: 
eNOS expression, eNOS localization, and eNOS activation.43 
i. eNOS expression: Although the eNOS gene is constitutively expressed in endothelial 
cells, it is regulated by multiple compounds and conditions. An up-regulation of eNOS 
expression is controlled by biophysical stimuli (e.g. shear stress and chronic exercise), 
hormones (e.g. estrogens, insulin, angiotensin II, endothelin 1), and phorbol esters. 
Cell proliferation as well as growth factors [i.e. transforming growth factor (TGF)-ß, 
fibroblast growth factors (FGFs), vascular endothelial growth factor (VEGF) and 
platelet-derived growth factor (PDGF)] are important stimuli for eNOS expression in 
vascular endothelial cells. In contrast, tumor necrosis factor-α (TNF-α) and bacterial 
lipopolysaccharide (LPS) down-regulate the expression of this enzyme.44 
ii. eNOS localization: Because NO is an extremely reactive and short-lived signaling 
molecule, its subcellular distribution is mainly determined by the subcellular 
localization of the eNOS and its local production. Subcellular localization and 
trafficking of endothelial NO synthase is controlled by co- and post-translational lipid 
modifications. eNOS is modified by myristoylation of a glycine residue and dual 
palmitoylation of cysteine residues, which targets the enzyme to the plasma 
membrane. A major pool of eNOS residues at the cytosolic face of Golgi complex, 
with smaller pools in caveolae, the plasma membrane cholesterol-rich microdomains, 
and endothelial junctions, indicating the presence of discrete localization of eNOS.45-47 
iii. eNOS activation: Multiple mechanisms are involved in regulating NO production 
following eNOS activation. eNOS activity is regulated firstly by Ca2+/CaM, followed 
by phosphorylation on multiple residues and finally through protein-protein-
interactions. All three aspects are briefly discussed below and summarized in Figure 
2.7. First, elevation of the intracellular concentration of free Ca2+ plays a crucial role 
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in eNOS activation and regulation. Free calcium will bind to CaM and the newly 
formed Ca2+/CaM complex in turn will bind to the CaM binding site. In caveolae of 
endothelial cells eNOS is held inactive by its association with caveolin-1 (cav-1). The 
association with cav-1 is counteracted by calcium-activated CaM, which leads to the 
dissociation of eNOS from caveolin-1 and finally increases eNOS enzymatic activity. 
Second, the effects of eNOS phosphorylation on specific serine and threonine residues 
are complex and involve numerous kinases and phosphatases. The two most 
thoroughly studied sites are the activating phosphorylation site Ser1177 and the 
inhibitory site Thr495. Several protein kinases including protein kinase B (PKB)/Akt 
(briefly discussed in section 2.4.3), protein kinase A (PKA) and AMP-activated 
protein kinase (AMPK) activate eNOS by phosphorylation of Ser1177 in response to 
various stimuli. In contrast, bradykinin and hydrogen peroxide activate eNOS activity 
by promoting Thr495 dephosphorylation. Finally, diverse phosphatases have been 
implicated in the regulation of eNOS dephosphorylation and modulate eNOS activity. 
As an example, protein phosphatase 2A catalyzes dephosphorylation of the activation 
site Ser1177. Third, in recent years several proteins have been described that directly 
associate with endothelial NOS and regulate its activity or spatial distribution in the 
cell. A positive impact on eNOS function involves the molecular chaperon HSP90 
(heat-shock protein 90), which participates in protein folding and signal transduction. 
On the other hand, eNOS is inhibited by binding to certain G-protein coupled 
receptors such as angiotensin II type 1 (AT1) or bradykinin B2. The nitric oxide 
synthase-interacting protein (NOSIP) and the nitric oxide synthase traffic inducer 
(NOSTRIN) can negatively regulate eNOS localization in the plasma membrane.48-52 
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Figure 2.7 Mechanisms of eNOS activation. 
eNOS activity is regulated by Ca2+/calmodulin (CaM), phosphorylation on multiple residues 
and/or through protein-protein-interactions [e.g. direct association with heat-shock protein 90 
(HSP90)]. 
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Since NO has potent and diverse biological effects and an NO deficiency plays a major role in 
endothelial dysfunction, the discussed control mechanisms of the enzyme eNOS are of great 
pathophysiological importance. The focus on an enhanced expression and/or activation of 
eNOS in response to pharmacological interventions could provide a promising approach to 
cardiovascular diseases. 
2.4.3 Role of the PI3K/Akt pathway in nitric oxide signaling 
Phosphoinositide 3-kinases (PI 3-kinases or PI3Ks) are a family of related enzymes, 
organized into three classes; I, II, and III, which are activated by tyrosine kinase and  
G-protein-coupled receptors, respectively. The PI3Ks are heterodimeric molecules composed 
of a regulatory (p85) and a catalytic (p110) subunit. Following its recruitment to these 
receptors in the plasma membrane, PI3K phosphorylates the 3’-inositol position of the 
membrane associated phosphoinositide(4,5)bisphosphate (PIP2) generating the second 
messenger phosphoinositide(3,4,5)trisphosphate (PIP3). PIP3 does not directly activate the 
protein kinase B, in the following denoted as Akt, but instead appears to recruit Akt to the 
inner leaflet of the plasma membrane and alters its conformation to allow subsequent 
phosphorylation by the phosphoinositide-dependent kinase-1 (PDK-1).  
The serine/threonine kinase Akt contains two regulatory phosphorylation sites, Thr308 in the 
activation loop within the kinase domain and Ser473 in the C-terminal regulatory domain. 
Thr308 is phosphorylated by PDK-1 leading to a partial activation of Akt. In order to obtain 
full activation of the kinase, the phosphorylation on the second site (Ser473) is also required. 
It is suspected that Ser473 is most likely targeted by the mammalian target of rapamycin 
(mTOR)-Rictor complex, however, the true mechanism remains to be elucidated. Once it has 
been fully activated by phosphorylation of both sites, Akt regulates several cellular functions 
including nutrient metabolism, cell growth, angiogenesis, apoptosis, and survival. Moreover, 
Akt mediates direct eNOS phosphorylation at Ser1177 (in human eNOS, equivalent to 
Ser1179 in bovine eNOS) and increases eNOS activity leading to NO release and 
vasodilation. The described signaling pathway is displayed in Figure 2.8 and can be inhibited 
by wortmannin. Wortmannin is a product of the fungus Penicillium fumiculosum that 
specifically inhibits PI3Ks.53-57 
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Figure 2.8 Activation of eNOS and nitric oxide release by PI3K/Akt signaling 
The phosphoinositide 3-kinases (PI3Ks) are heterodimeric molecules composed of a regulatory 
(p85) and a catalytic (p110) subunit. They convert the phosphoinositide(4,5)bisphosphate 
(PIP2) to phosphoinositide(3,4,5)trisphosphate (PIP3) on the inner leaflet of the plasma 
membrane. PIP3 produced by phosphorylation leads to the activation of the PDK/Akt pathway 
resulting in eNOS phosphorylation and NO release. All PI 3-kinases are inhibitable by 
wortmannin. 
 
2.5 Angiogenesis 
Angiogenesis is the process of the development and growth of new blood vessels from pre-
existing vasculature. It plays a key role in various physiological and pathological conditions, 
including embryonic development, normal tissue growth, wound healing, the female 
reproductive cycle (i.e. ovulation, menstruation and placental development), as well as in the 
development of numerous types of tumor. Without blood vessels, tumors can not grow 
beyond a critical size of few mm³ and metastasize to another organ. As early as 1971, 
Folkman proposed that tumor growth and metastasis are angiogenesis-dependent, and 
therefore, blocking angiogenesis could be a strategy to arrest tumor growth.58 The onset of 
angiogenesis, or the “angiogenic switch”, is regulated by both pro-angiogenic and anti-
angiogenic molecules that can occur at any stage of tumor progression.59 Normally, the effect 
of activator molecules is balanced by that of inhibitor molecules blocking growth. Should a 
need for new blood vessels arise, the net balance is tipped in favor of angiogenesis. Various 
signals that trigger the angiogenic switch have been discovered. These include metabolic 
stress, mechanical stress or genetic mutations. Furthermore, the process of angiogenesis 
implies complex cellular and molecular interactions between cancerous cells, endothelial cells 
and the components of the extra-cellular matrix.60, 61 
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2.5.1 Angiogenesis cascade 
Angiogenesis is a multi-step process induced by the release of angiogenic signals from 
diseased tissue or cancer cells into the surrounding area. When angiogenic growth factors 
encounter endothelial cells, they bind to specific receptors located on the outer surface of the 
cells. The binding of the growth factor to its appropriate receptor activates a series of relay 
proteins that transmit a signal into the nucleus of ECs. Activation of ECs leads to the 
localized degradation of the basal membrane of the parent vessel and of the extra-cellular 
surrounding. The endothelial cells begin to proliferate and migrate into the perivascular space 
towards chemotactic angiogenic stimuli from the diseased tissue (tumor). This leads to the 
formation of solid endothelial cell sprouts into the stromal space. Additional enzymes (e.g. 
matrix metalloproteinases) are produced from either tumor or endothelial cells to dissolve the 
tissue in front of the sprouting vessel tip in order to accommodate it. Then, vascular loops are 
formed and capillary tubes are developed by formation of tight junctions and a deposition of 
new basement membrane.62 In contrast to physiological normal vessels, the tumor vasculature 
significantly differs and is highly disorganized. Differences include an abnormal blood flow, 
altered endothelial cell-pericyte interactions, increased permeability, delayed maturation and 
an aberrant vascular structure. The latter means that tumor vessels are irregular shaped, 
tortuous and dilated, with uneven diameter, excessive branching and shunts.59, 60 
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Figure 2.9 Key steps in angiogenesis. 
The angiogenesis cascade occurs as an orderly series of events. Angiogenic endothelial cells 
must proliferate, avoid apoptosis, migrate, produce molecules able to degrade the extracellular 
matrix and, finally, differentiate into new vascular tubes. The image is adapted from 
http://www.angio.org/understanding/understanding.html. 
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In summary, angiogenic signals promote endothelial cell proliferation, increase resistance to 
apoptosis, initiate the degradation of the extracellular matrix (ECM), change endothelial 
adhesive properties, induce migration, and finally differentiation as well as the formation of a 
new vascular lumen (Figure 2.9). 
During angiogenesis the regulation of endothelial behavior is the result of a very complex 
network of intracellular signaling systems. The major pathways are:  
i. the mitogen-activated protein kinase pathway, which is very important in the 
transduction of proliferation signals and detailed described in section 2.5.2; 
ii. the phosphatidylinositol-3-kinase/protein kinase B signaling system, particularly 
essential for the survival of the angiogenic endothelium; 
iii. the small GTPases involved in cytoskeletal reorganization and migration; 
iv. the kinases associated to focal adhesions which contribute to integrate the pathways 
from the extracellular matrix and growth factors.63 
 
2.5.2 Mitogen activated kinases 
As aforementioned, the mitogen-activated protein kinases (MAPKs) pathway presents one 
signaling system leading to angiogenesis. MAPKs are a family of serine/threonine kinases 
that respond to a wide variety of stimuli including growth factors, cytokines and 
environmental stresses. 
In mammalian cells, there are more than a dozen MAPK genes. The best known genes are:  
(i) the extracellular signal-regulated kinases 1 and 2 (ERK1/2); (ii) c-Jun N-terminal kinases 
(JNK (1-3)); and (iii) the p38 kinase isozyme (p38α, β, γ, and δ) families. These three major 
MAPK families are implicated in a variety of human diseases and thus prominent targets for 
drug development. MAPKs regulate critical cellular functions required for homeostasis such 
as the expression of cytokines and proteases, cell cycle progression, cell adherence, motility 
and metabolism. In brief, MAPKs influence cell proliferation, differentiation, survival, 
apoptosis and development.64 
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MAPKs are similar in their activation by dual phosphorylation of conserved threonine and 
tyrosine residues within the activation loop (known as Thr-X-Tyr motif). Moreover, each 
MAPK pathway contains a core triple kinase cascade comprising an apical MAP kinase 
kinase kinase (also denoted as MAPKKK, MAP3K, MEKK or MKKK), a MAP kinase kinase 
(also known as MAPKK, MAP2K, MEK or MKK) and a downstream MAP kinase.65 This 
core module is summarized in Figure 2.10. 
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Figure 2.10 Activation of all MAPKs is regulated by a central three-tiered core signaling module. 
The three-tier module mediates responses to stimuli like growth factors, cytokines or stress 
factors and activates the apical MAP kinase kinase kinase (MAPKKK). This activation leads to 
a dual phosphorylation of serine residues of the MAP kinase kinase, which in turn activate 
MAPKs by phosphorylation on threonine and tyrosine residues. The active MAPKs frequently 
translocate from the cytoplasm to the nucleus to phosphorylate nuclear targets. 
These signal transduction pathways are organized as communication networks that process 
and integrate information. Their relay stations are formed by multiprotein complexes. 
Therefore, the pathway specificity is regulated at several levels, including kinase-kinase and 
kinase-substrate interactions, colocalization of kinases with scaffold proteins and inhibitors. 
The described dynamic spatial control of MAPK signaling networks contributes to the highly 
specific physiological responses in cells, organs and organisms.66, 67 
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Extracellular signal-regulated kinase (ERK) cascade 
The isoforms ERK1 and ERK2, often referred to as p44 and p42 MAPKs, contain a  
Thr-Glu-Tyr motif within the activation loop of the kinase domain and are activated by 
mitogenic stimuli such as growth factors (as described in section 2.5.3), serum, cytokines and 
phorbol esters, which activate a variety of receptors and G proteins.68 The ERKs are 
expressed in many tissues and form a part of a MAPK module that includes the Raf family 
kinases (MAPKKKs) and the MEK 1/2 MAPKK. 
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Figure 2.11 The ERK cascade. 
In the three-tier module the apical MAP kinase kinase kinase (MAPKKK) Raf is activated. 
This activation leads to a dual phosphorylation of serine residues of the MAP kinase kinase 
MEK 1/2, which in turn activate ERK 1/2 by phosphorylation on Thr and Tyr. 
The critical link that allows signal transduction from RTKs to ERK is the activation of Raf 
family kinases (comprised of A-Raf, B-Raf and C-Raf/Raf-1). The serine/threonine kinase 
Raf is activated via membrane localization, cycles of phosphorylation/dephosphorylation and 
protein binding.69, 70 Once activated, all Raf family members are capable of initiating the 
phosphorylation cascade, in which Raf activates the MAPK/ERK kinases 1 and 2 (MEK 1/2) 
by phosphorylation of two serine residues within their activation segment.69 This dualspecific 
MEK 1/2 in turn activates ERK via phosphorylation of threonine and tyrosine residues in the 
ERK activation loop. However, in contrast to the complexity observed in Raf activation, 
MEK 1/2 and ERK become fully activated simply through the dual phosphorylation of the 
activation segments in their respective kinase domains.71 A schematic representation of the 
MAPK cascade comprised of Raf, MEK 1/2 and ERK kinases (known as the ERK cascade) is 
displayed in Figure 2.11. 
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The ultimate goal in RTK downstream signaling is achieved when active ERK1 and ERK2 
phosphorylate crucial targets in the nucleus, cytosol, membranes and cytoskeletal 
compartments. These targets are required to carry out the cellular response specified by the 
initiating signal. Identified ERK substrates include: 
i. key transcription factors, such as AP-1, NF-кB, ELK1, cFOS, c-Myc and Ets; 
ii. several protein kinases, such as p90 ribosomal S6 kinase (RSK), mitogen and stress 
activated kinase (MSK) and MAPK-interacting kinase (MNK); 
iii. proteins involved in cell attachment and migration, including myosin light chain 
kinase (MCLK) and focal adhesion kinase (FAK).72 
Finally, ERK regulates diverse cellular mechanisms including embryogenesis as well as 
angiogenesis, proliferation, cell motility, differentiation and apoptosis. These programs are 
based on signals derived from the cell environment, surface, and the metabolic state of the 
cell. In particular, aberrant regulation of the ERK pathway contributes to cancer. Additionally, 
ERK activation is a fundamental step in bFGF- and VEFG-induced angiogenesis. Because of 
this key role the ERK pathway has been in focus for drug discovery for almost 15 years with 
Ras, Raf and MEK 1/2 being the main targets.73, 74 Inhibition of ERK activation, therefore, 
represents a valid approach for anti-angiogenic therapy and cancer treatment. 
2.5.3 Growth factors 
In recent years more than a dozen different proteins, as well as several smaller molecules, 
have been identified as angiogenic factors, meaning that these proteins are released by tumors 
as angiogenesis-inducing signals. Among these molecules, two proteins appear to be the most 
important ones: basic fibroblast growth factor (bFGF) and vascular endothelial growth factor 
(VEGF).75 Both angiogenic growth factors are produced by various kinds of cancer cells and 
by certain types of normal cells, too. Currently, bFGF and VEGF are targets of great interest 
to inhibit deregulated blood vessel formation. Thus, concentrated efforts in this area of 
research led to development of inhibitors of bFGF and VEGF signaling. Some are already in 
clinical trials or therapeutically used. Examples of angiogenesis inhibitors which bind to and 
inhibit the biological activity of human VEGF are bevacizumab (Avastin®, Genentech, Inc., 
CA, USA, humanized anti-VEGF antibody) and ranibizumab (Lucentis®, Genentech, 
antibody fragment designed for intraocular use).76-78 
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Basic fibroblast growth factor 
Basic fibroblast growth factor (bFGF), also denoted as FGF-2, was the first pro-angiogenic 
molecule to be identified.79 bFGF is a prototypic member of a family comprising 22 proteins, 
which was first purified as a heparin-binding polypeptide from a bovine pituitary. It was 
subsequently characterized as a 18 kDa (low molecular weight; LMW) basic protein due to its 
high isoelectric point.80 The ubiquitous bFGF is one of the most potent angiogenic factors, 
possesses neuron-protective properties, and is implicated in vascular remodeling and tumor 
metastasis. The terminus bFGF comprises distinct isoforms that are generated by alternative 
initiation of translation on a single mRNA. These alternative isoforms of bFGF, collectively 
referred to as high molecular weight bFGF (HMW), have different subcellular localizations 
and functions.81, 82 The LMW-bFGF is primarily located in the cytoplasm, but can also be 
released from dead or injured cells. In the extracellular matrix it is associated with heparan-
sulfate proteoglycans. Along this line, LMW-bFGF functions in an autocrine and paracrine 
manner, whereas HMW-bFGF isoforms are nuclear and exert activities through an intracrine 
mechanism. Furthermore, LMW-bFGF exerts its effects via specific binding and activation of 
four different receptor tyrosine kinases (RTKs) designated FGFR1, FGFR2, FGFR3 and 
FGFR4. Unlike other growth factors, bFGF acts in concert with heparin or heparan sulfate 
proteoglycan (HSPG) to activate RTKs by forming a ternary complex. Activation of the 
receptor kinase activity via receptor dimerization and intermolecular autophosphorylation of 
specific tyrosine residues allows coupling to downstream signal transduction pathways that 
have been associated with multiple biological activities, including proliferation, migration and 
differentiation of endothelial cells. Several intracellular signaling cascades are known to be 
activated by binding of bFGF to its receptors, including the phospholipase C-γ (PLC-γ) 
pathway, the PI3K-Akt pathway and the Ras-MAP kinase pathway. The latter signal 
transduction cascade is mainly activated by binding of bFGF to the FGFR1 and is briefly 
described below (Figure 2.12).83, 84 
The activated FGFR1 becomes a platform for the recognition and recruitment of a specific 
complement of adaptors, enzymes or docking proteins. One of these adaptor proteins is the 
growth factor receptor bound protein 2 (Grb2). The recruitment of Grb2 from the cytoplasm 
to the plasma membrane brings the associated guanine nucleotide exchange factor son of 
sevenless (SOS) near to the membrane-bound proto-oncogene Ras. Through guanine 
exchange, SOS enhances GDP release and GTP binding to Ras, converting this small GTPase 
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into its active conformation. This conformational activation of Ras allows the interaction of 
various downstream target effectors, including the mitogen activated protein kinase kinase 
kinases (MAPKKK) Raf. Activated Raf kinases are the point of entry into the three-tiered 
kinase cascade in which Raf phosphorylates the MAPK/ERK kinases 1 and 2 (MEK 1/2), and 
MEK 1/2 in turn phosphorylates and activates the extracellular signal-regulated kinases 
1 and 2 (ERK 1/2) as described in section 2.5.2. A number of angiogenic inhibitors have been 
discovered that are able to antagonize bFGF activity, among them platelet factor-4 (PF-4), 
angiostatin, endostatin and the 16 kDa human prolactin fragment (16 kDa hPRL). 
 
Grb2
Ras
GDP
Ras
GTP
P P
PRaf
P
P
ERK 1/2
P
MEK 1/2
P
SOS
Proliferation
Migration
Tube formation
FGFR
MAPKKK
MAPK
MAPKK
P
P
P
P
FGF
cytosol
extra-
cellular
endothelial cell
 
 
Figure 2.12 FGF binding to FGFRs activates the Ras-MAP kinase pathway. 
Upon ligand binding, receptor dimers are formed and their intrinsic tyrosine kinase is activated 
causing phosphorylation of multiple tyrosine residues on the receptor. Subsequently, signaling 
complexes are assembled and recruited to the active receptor leading to activation of the Ras-
MAP kinase pathway. 
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Vascular endothelial growth factor 
Vascular endothelial growth factors (VEGFs) are crucial regulators of vascular development 
during embryogenesis (vasculogenesis) as well as blood-vessel formation (angiogenesis). 
During the last few years, several members of the vascular endothelial growth factor (VEGF) 
family have been described including VEGF-A, B, C, D, E and the placenta growth factor 
(PIGF). All members of the VEGF family are dimeric glycoproteins belonging to the platelet 
derived growth factor (PDGF) superfamily.85 Among these proteins VEGF-A, also referred to 
as vascular permeability factor (VPF), plays an important role in angiogenesis. Consonant 
with its pivotal role in vascular development, VEGF-A is a multi-tasking cytokine, which 
stimulates endothelial cell proliferation, migration, survival and differentiation. Moreover, 
VEGF-A increases vascular permeability, causes vasodilation (partly through stimulation of 
NO synthase in endothelial cells), induces tubulogenesis and influences gene expression.86-88 
The prominent role of VEGF in angiogenesis has been demonstrated utilizing mice lacking a 
VEGF allele. These mice die in utero between day 11 and 12, probably due to defective 
vascularization.89, 90 
The multifunctionality of VEGF-A at the cellular level results from its ability to initiate a 
diverse, complex and integrated network of signaling pathways. It either binds to one of the 
three receptor tyrosine kinases (RTKs), known as VEGF receptor-1, -2 and -3 (VEGFR1-3), 
and/or co-receptors such as heparan sulfate proteoglycans (HSPGs) and neurophilins 
(multifunctional transmembrane glycoproteins).91 Most, if not all, biologically relevant 
VEGF-A signaling in endothelial cells is mediated via VEGFR2, also denoted as the kinase 
domain region (KDR) or Flk-1. The VEGFR2 is activated through ligand-stimulated receptor 
dimerization and trans(auto)phosphorylation of multiple tyrosine residues in the cytoplasmic 
domain. A major mitogenic signaling mechanism for VEGF-A is the phospholipase C-γ 
(PLC-γ) pathway. VEGF-A induces strong PLC-γ tyrosine phosphorylation and activation 
leading to hydrolysis of phosphatidylinositol 4,5-bisphosphate, and thereby generation of 
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol and subsequent activation of the protein 
kinase C (PKC). PKC mediates direct activation of Raf-1, which in turn leads to the activation 
of MEK 1/2 (mitogen-activated protein kinase/ERK kinase 1/2) and extracellular-signal-
regulated protein kinase 1 and 2 (ERK 1 and ERK 2).92-94 The described PLC-γ pathway is the 
main signaling mechanism in VEGF-induced ERK activation (Figure 2.13). However, to a 
minor extent ERK activity is also enhanced by VEGF through the Ras-dependent pathway.95 
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Figure 2.13 VEGF binding to KDR activates the MAPK pathway. 
Upon VEGF binding, the KDR dimerize and autophosphorylates tyrosine residues. 
Subsequently, downstream signaling molecules including the MAP kinases are activated. 
2.5.4 Protein phosphatases 
Protein phosphorylation plays a crucial role in regulating various cellular processes. Along 
this line, target proteins are phosphorylated at specific sites by one or more protein kinases, 
and these previously “attached” phosphate residues are later on removed by specific protein 
phosphatases (Figure 2.14). Kinases and phosphatases are counterparts that function in a 
strictly organized and coordinated manner to tightly control signaling pathways. The level of 
protein phosphorylation reflects the balance between kinase and phosphatase activity. Protein 
phosphatases can be classified into three groups on the basis of sequences, structures and 
catalytic mechanisms. The three distinct groups are categorized as follows: serine/threonine 
phosphatases (PPs), protein tyrosine phosphatase (PTP), and aspartame-based protein 
phosphatases. 
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Figure 2.14 The Yin and Yang of protein phosphorylation 
Target proteins are phosphorylated by protein kinases. The phosphate residues are removed by 
protein phosphatases. 
2.5.4.1 Protein serine/threonine phosphatases 
Initially the protein serine/threonine phosphatases (PPs) were classified as either type-1 (PP1) 
or type-2 (PP2) according to biochemical parameters. Type-1 protein phosphatases (PP1) are 
inhibited by heat-stable inhibitor proteins and preferentially dephosphorylate the ß-subunit of 
phosphorylase kinase. In contrast, type-2 protein phosphatases (PP2) are insensitive to these 
inhibitors and preferentially dephosphorylate the α-subunit of phosphorylase kinase. The 
type-2 enzymes were further subdivided into spontaneously active protein phosphatase 
(PP2A, does not require metals for activation), Ca2+-stimulated protein phosphatase (PP2B, 
also known as calcineurin) and the Mg2+-dependent protein phosphatase (PP2C). Further 
experimentation with cDNA cloning revealed that PP1, PP2A and PP2B belong to the same 
gene family, whereas PP2C is structurally different. 
Today, PPs are subdivided into the phosphoprotein phosphatase (PPP) and Mg2+-dependent 
protein phosphatase (PPM) gene families on the basis of metal-ion requirements and substrate 
specificity (Figure 2.15). The PPP family includes the most abundant protein phosphatases: 
PP1, PP2A and PP2B, whereas the PPM family comprises the PP2C isoforms. PPs catalyze 
the direct hydrolysis of phosphosubstrate, a process that is facilitated by two metalions at the 
active centre of the enzyme. 
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Figure 2.15 Serine/threonine phosphatases (PPs) 
The family of PPs comprises the large phosphoprotein phosphatase (PPP) family and the 
protein phosphatase Mg2+-dependent (PPM) family. The active centre of these enzymes 
contains a metal-ion (Fe2+ and Zn2+ or Mn2+), which are required for catalysis. 
Protein phosphatase 2A (PP2A) 
PP2A is a major regulator of growth-regulatory signal transduction pathways and 
proliferation. The PP2A multi-tasking enzyme system is the cellular target of okadaic acid 
and exerts positive as well as negative functions due to its distinct subcellular location and 
diverse substrate specificity. Recent studies have demonstrated that PP2A functions as 
positive regulator of Raf-1 and kinase suppressor of Ras via dephosphorylation of 
phosphorylated serine and threonine residues that inhibit kinase activity. PP2A activity is 
required for the membrane translocation of the scaffold protein kinase suppressor of Ras 1 
(KSR1), which interacts with kinase components of the ERK cascade and facilitates signal 
transmission from Raf-1 to MEK 1/2 and ERK.96-100 
2.5.4.2 Protein tyrosine phosphatases 
Protein tyrosine phosphatases (PTPs) encode the largest family of phosphatase genes and are 
divided into the classical, phosphotyrosine-specific phosphatases and the dual specificity 
phosphatases (DUSPs) (summarized in Figure 2.16). These enzymes share an identical 
catalytic mechanism and a common CX5R sequence motif, in which the thiol group of an 
active site cysteine residue functions as the attacking nucleophile. The classical PTPs include 
transmembrane receptor-like proteins (RPTPs) that have the potential to regulate signaling 
through ligand-controlled protein tyrosine dephosphorylation. Many of the RPTPs, 
exemplified by DEP-1, LAR and PTPα, generally contain extracellular domains often 
resembling adhesion receptors and have been implicated in processes that involve cell-cell 
26  2  INTRODUCTION 
and cell-matrix contact.101, 102 The cytoplasmic PTPs, i.e. SHP-1, SHP-2 and PTP1B, are 
characterized by regulatory sequences that flank the catalytic domain and control activity 
either directly or by regulating substrate specificity. Members of dual specificity phosphatases 
are the MAPK phosphatases (i.e. MKP-1 and MKP-3), the cell cycle regulators Cdc25 
phosphatases, and the tumor suppressor PTEN.103 All PTPs are characterized by their 
sensitivity to vanadate, the ability to hydrolyze p-nitrophenyl phosphate, an insensitivity to 
okadaic acid and a lack of metal ion requirement for catalysis.104 
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Figure 2.16 Protein tyrosine phosphatases (PTPs) 
The family of PTPs can be divided into the classical, phosphotyrosine-specific phosphatases 
and the dual specificity phosphatases (DUSPs). Moreover, the first group of PTPs can be 
categorized as receptor–like or cytosolic phosphatases. The active centre of these enzymes 
contains a cysteine residue. 
In the following two PTPs are briefly discussed, which can inactivate the growth factor-
induced ERK phosphorylation working at different steps of the described signaling cascade. 
The MAP kinase phosphatase MKP-1 
Members of the MAPK family could be rapidly inactivated through dephosphorylation by 
PTPs known as dual specificity mitogen-activated protein kinase phosphatases (DUSPs, also 
referred to as MKPs). Among these phosphatases, MKP-1, encoded by an immediate early 
gene, inactivates ERK by dephosphorylation of the two critical MAPK residues 
(Thr202/Tyr204) accountable for its activation. It was also shown that MKP-1 
dephosphorylates and inactivates the p38 MAPK as well as JNK. MKP-1 is widely 
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distributed, however, expressed at low levels. Therefore, MKP-1 underlies a rapid and tight 
transcriptional upregulation in response to numerous stimuli, including mitogens like growth 
factors, oxidative stress, heat shock or hormones.105-107 
The src homology-2 (SH2) domain-containing PTPs 
The src homology-2 (SH2) domain-containing PTPs (SHPs) are a subfamily of the classical 
cytosolic PTPs composed of two SH2 domains (one within the NH2-terminal half and another 
within the C-terminal half) and the proteintyrosine-binding (PTB) domain (Figure 2.17). 
There are two vertebrate SHPs: SHP-1 (also denoted as SH-PTP1 or PTP1C) and SHP-2 (also 
denoted as SH-PTP2 or PTP2C). It is intriguing that despite their close sequence and 
structurally homology these two phosphatases play quite different and often opposing cellular 
roles.108-110 
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Figure 2.17 Structure of Src homology-2 (SH2) domain-containing phosphatase 
A schematic of a typical member of the SHP subfamily is shown, indicating the two SH2 
domains (N-SH2 and C-SH2) and the catalytic protein-tyrosine phosphatase domain. 
 
SHP-2 plays a mainly positive signaling role in the Raf-MEK-ERK pathway. In contrast, 
SHP-1 acts as a largely negative signaling role suppressing cellular activation and ERK 
phosphorylation. Recent studies have demonstrated that SHP-2 positively regulates signaling 
downstream of the insulin receptor, epidermal growth factor receptor (EGFR), platelet-
derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR). 
Contrary to these findings, SHP-1 interacts with activated cytokines, growth factors, and 
antigen receptors and performs a negative regulatory role in signaling pathways by 
dephosphorylation of the receptors or receptor substrates to which it binds. Thus, treatment of 
endothelial cells with TNF-α increases SHP-1 activity and consequently, attenuates growth 
factor-induced ERK phosphorylation. Activation of VEGF receptor-2 by VEGF has been 
shown to enhance SHP-1 activity resulting in the dephosphorylation of VEGFR-2 and the 
28  2  INTRODUCTION 
MAP kinase ERK. Finally, elevated SHP-1 activity weakens VEGF-induced endothelial 
proliferation.111-113  
SHP-1 has been proposed to be a potential tumor suppressor gene in leukemia, lymphoma and 
other cancers. It is also believed that its expression might be diminished in some cancers. In 
contrast to hematopoietic cancers, SHP-1 proteins were reported to be over-expressed in 
epithelial cancers such as prostate, ovarian and breast cancers. These data suggest that SHP-1 
can play either negative or positive roles in regulating signal transduction pathways. In 
summary, SHP-1 plays a role in the negative regulation of growth factor-induced cellular 
effects and appears to be a key molecule in the prevention of endothelial dysfunction  
(i.e. atherogenesis) and in the induction of angiogenesis in ischemic diseases.114, 115 
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3.1 Materials 
The following materials were used for cell culture and animal experiments. 
3.1.1 Ginkgo biloba extract - EGb 761 
EGb 761 is a well-defined preparation of Ginkgo biloba leaves and was kindly provided by 
Dr. Willmar Schwabe Pharmaceuticals (Karlsruhe, Germany). The composition, therapeutic 
uses as well as actions are described in section 2.2. The chemical structures of the main 
compounds of EGb 761 are displayed in the same section. 
For experiments, EGb 761 was freshly dissolved in growth medium at a maximal 
concentration of 1,000 µg/ml. 
3.1.2 Biochemicals and inhibitors 
 
Biochemicals  
A23187 Alexis Biochemicals, San Diego, CA, USA 
FGF PeproTech, Rocky Hill, NY, USA 
Forskolin Biotrend Chemikalien GmbH, Cologne, Germany 
IBMX Applichem, Darmstadt, Germany 
PDGF Sigma, Taufkirchen, Germany 
PMA Sigma, Taufkirchen, Germany 
VEGF PeproTech, Rocky Hill, NY, USA 
 
 
Inhibitors  
cAMPS-Rp Biotrend, Cologne, Germany 
L-NAME Cayman Chemical Company, Michigan, USA 
Na3VO4 ICN Biomedicals, Aurora, Ohio, USA 
NaF Merck, Darmstadt, Germany 
PKA inhibitor fragment (6-22) Biotrend, Cologne, Germany 
U0126 Tocris, MO, USA 
Wortmannin Alexis Biochemicals, San Diego, CA, USA 
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3.2 Cell culture 
3.2.1 Solutions and Reagents 
The following solutions and reagents were used for either isolation or culture of ECs. 
 
PBS (pH 7.4)   PBS Ca2+/Mg2+ (pH 7.4) 
NaCl 123.2 mM  NaCl 137 mM 
Na2HPO4 10.4 mM  KCl 2.68 mM 
KH2PO4 3.2 mM  Na2HPO4 8.10 mM 
    KH2PO4 1.47 mM 
    MgCl2 0.25 mM 
    CaCl2 0.50 mM 
    H2O   
 
Trypsin/EDTA (T/E)   Collagen G solution 
Trypsin 0.05 %  Collagen G 0.001 % 
EDTA 0.20 %  PBS   
PBS       
 
Cell Culture Reagents  
Aminopteridine PAN Biotech, Aidenbach, Germany 
Amphotericin B PAN Biotech, Aidenbach, Germany 
Collagen G BIOCHROME AG, Berlin, Germany 
Collagenase A Roche, Mannheim, Germany 
Culture flasks, plates, dishes TPP, Trasadingen, Switzerland 
DMEM without Phenolred Cambrex, Verviers, Belgium 
ECGM with supplement mix Provitro, Berlin, Germany 
FBS BIOCHROME AG, Berlin, Germany 
Glutamine PAN Biotech, Aidenbach, Germany 
Hypoxanthine PAN Biotech, Aidenbach, Germany 
M199 PAN Biotech, Aidenbach, Germany 
Penicillin PAN Biotech, Aidenbach, Germany 
Streptomycin PAN Biotech, Aidenbach, Germany 
Thymidine PAN Biotech, Aidenbach, Germany 
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Fetal bovine serum (FBS) 
FBS 880FF tested for mycoplasm and endotoxin was supplied by Biochrome AG (Berlin, 
Germany). For heat inactivation, FBS was partially thawed for 30 min at room temperature. 
Subsequently, it was totally thawed at 37°C using a water bath. Finally, inactivation was 
performed at 56°C for 30 min. Thereafter, FBS was aliquoted and stored at -20°C. 
Charcoal-stripped FBS 
FBS contains a significant amount of different steroids like estrogens. These steroids can 
influence the experiments, e.g. endothelial nitric oxide synthase (eNOS). Therefore, these 
experiments were performed with charcoal-stripped FBS. Heat-inactivated FBS (100 ml) 
were gently swirled with 2 g activated charcoal overnight at 4°C. Afterwards, FBS was 
cleaned from charcoal by repeated centrifugation (2x 5 min, 4,000 U/min and 1x 1 h, 
1,000 U/min, respectively). Thereafter, the serum was sterile filtrated (Steritop 0.22 µM, 
Millipore, Germany), aliquoted and frozen at -20°C. 
3.2.2 Endothelial cells 
Endothelial cells were cultured in a humidified atmosphere at 37°C and 5% CO2 in an 
incubator (Heraeus, Hanau, Germany). Furthermore, the cells were routinely tested for 
contamination of Mycoplasma with the PCR detection kit VenorGeM (Minerva Biolabs, 
Berlin, Germany). 
3.2.2.1 Cell lines 
HMEC-1 − Human microvascular endothelial cells 
The cell line CDC/EU.HMEC-1 (commonly termed HMEC-1) was kindly provided from 
Centers for Disease Control and Prevention (Atlanta, GA, USA). HMEC-1 is an immortalized 
cell line (human dermal microvascular endothelial cells transfected with a plasmid coding for 
the transforming SV40 large T-antigen) that has been shown to retain endothelial 
morphologic, phenotypic, and functional characteristics.116, 117 
HMECs were used for all experiments regarding the topic angiogenesis including Western 
blot analysis, angiogenesis Assays except migration, cAMP Assay and serine/threonine 
phosphatase Assay. 
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HMEC growth medium    
ECGM 500 ml     
Supplement 10 ml     
 
EA.hy926 
The human cell line EA.hy926 was graciously provided by Dr. C.-J. Edgell, University of 
North Carolina (Chapel Hill, NC, USA). EA.hy926 cells were derived by fusing human 
umbilical vein endothelial cells (HUVECs) with the permanent human lung carcinoma cell 
line A549. They represents a permanent cell line and are characterized as endothelial cells.117, 
118 EA.hy926 cells were cultured in EA.hy926 growth medium. All experiments referring to 
topic nitric oxide were performed using EA.hy926 cells. These are western blot analysis, 
[14C]L-arginine/[14C]L-citrulline conversion assay as well as immunohistochemistry and 
confocal laser scanning microscopy. 
 
EA.hy926 growth medium  
DMEM 500 ml    
Charcoal-stripped FBS 50 ml    
Glutamine 2 mM    
Hypoxanthine 100 µM    
Aminopterine 0.4 µM    
Thymidine 16 µM    
 
EA.hy926-heNOS-Luc 
EA.hy926 cells stably transfected with a plasmid containing 3,600 base pairs of the human 
eNOS promoter driving a luciferase gene (pNOSIII-Hu-3500-Luc-neo) were kindly provided 
by Dr. P. Wohlfart (Sanofi-Aventis, Germany).119 EA.hy926-heNOS-Luc cells were 
cultivated with EA.hy926 growth medium supplemented with the antibiotic G418 (400 µg/ml, 
Sigma, Taufkirchen, Germany) as a selection marker for transfected cells. Confluent cells 
were stimulated for 24 h with increasing concentrations of EGb 761 and used for luciferase 
reporter gene assays in order to determine eNOS promoter activity. 
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3.2.2.2 Primary cells 
Human umbilical vein endothelial cells (HUVECs) were prepared by digestion of umbilical 
veins with 0.1 g/l of collagenase A (37°C, 45 min).120 HUVECs were cultured in HUVEC 
growth medium and used for the following experiments: western blot analysis, cell migration 
and Raf-1 kinase Assay. Furthermore, all experiments referring to tyrosine phosphatase  
SHP-1 were performed using HUVECs. 
 
HUVEC growth medium    
ECGM 500 ml     
Supplement 10 ml     
FBS 50 ml     
Penicillin 100 U/ml     
Streptomycin 100 µg/ml     
Amphotericin B 2.5 µg/ml     
 
3.2.3 Passaging 
After reaching a confluent state, cells were either sub-cultured 1:3 in 75 cm² culture flasks or 
seeded in plates or dishes for experiments. For passaging, medium was removed and cells 
were washed twice with phosphate buffered saline (PBS) before they were incubated with 
trypsin/ethylene diamine tetraacetic acid (EDTA) (T/E) for 1-2 min at 37°C. Thereafter, cells 
were gradually detached and the digestion was stopped using passaging medium for either 
HUVECs or HMECs, or growth medium for EA.hy926 cells. After centrifugation at 
1,000 rpm for 5 min at room temperature the pellet was resuspended in growth medium. 
 
Passaging medium    
M199 500 ml     
FBS 50 ml     
Penicillin 100 U/ml     
Streptomycin 100 µg/ml     
Amphotericin B 2.5 µg/ml     
 
All HUVEC-experiments were performed with cells in passage number three. HMECs as well 
as EA.hy926 cells were used from passage number 3 up to 20 for experiments. 
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Culture flasks or plates were coated using collagen G solution before seeding HUVECs or 
HMECs. Therefore, Collagen G solution was added to plates or dishes and incubated for 
20 min at 37°C. 
3.2.4 Freezing and thawing 
For freezing, confluent HMECs or EA.hy926 cells from a 75 cm² flask were trypsinized, spun 
down (1,000 rpm, 5 min, 24°C) and resuspended in 3 ml ice-cold freezing medium. Aliquots 
with 1.5 ml were frozen in cryovials. After storage at -80°C for 24 h, aliquots were moved to 
liquid nitrogen for long term storage. 
For thawing, the content of a cryovial was warmed to 37°C and immediately dissolved in pre-
warmed growth medium. In order to remove DMSO from the cells, they were centrifuged at 
1,000 rpm for 5 min. After centrifugation, cells were resuspended in growth medium and 
transferred to a 75 cm² culture flask. 
 
 
HMEC freezing medium   EA.hy926 freezing medium 
FBS 50 %  FBS 10 % 
DMSO 8 %  DMSO 10 % 
ECGM    DMEM   
 
 
3.3 Western blot analysis 
Western blot analysis is an extensively used technique to identify proteins based on their 
ability to bind to specific antibodies in a given cell lysate or sample of tissue homogenate.  
In the first part of this section; the preparation of either in vitro or in vivo samples is 
explained. Afterwards, the separation of protein samples using SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) is described. Thereafter, the transfer of proteins to a membrane 
is introduced. This step is also denoted as “blotting“. Finally, proteins are visualized using 
monoclonal or polyclonal detection antibodies. 
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3.3.1 Preparation of samples 
In Vitro Samples 
Endothelial cells were grown in 6-well plates until confluence, starved in M199 for 4 h and 
treated as indicated in the respective figure legend. Subsequently, cells were washed with ice-
cold PBS and lyzed in Ripa lysis buffer. Immediately, cells were frozen at -85°C. Afterwards, 
cells were scraped off and transferred to Eppendorf tubes (Peske, Aindling-Arnhofen, 
Germany) before centrifugation (16,000 rpm, 10 min, 4°C). For adjustment of samples protein 
content, protein concentration was determined. Laemmli sample buffer (3x) was added to the 
remaining supernatant and samples were heated at 95°C for 5 min. Samples were kept at -
20°C until Western blot analysis. 
 
Ripa lysis buffer  Laemmli sample buffer (3x) 
NaCl 150 mM  Tris-HCl 187.5 mM 
Tris 50 mM  SDS 6 % 
Nonidet P-40 1.00 %  Glycerol 30 % 
Deoxycholat 0.25 %  Bromphenol blue 0.015 % 
SDS 0.10 %  H2O   
H2O    add before use:   
add before use:   ß-mercaptoethanol 12.5 % 
CompleteTM 4 mM     
PMSF 1 mM     
activated Na3VO4 1 mM     
NaF 1 mM     
 
In Vivo Samples 
Stimulation of Sprague-Dawley rats and isolation of thoracic aortas was kindly performed by 
Andreas Hartkorn (Ludwig-Maximilians-University of Munich, Department of Pharmacy – 
Centre of Drug Research). Briefly, in anesthetized Sprague-Dawley rats, a bolus of EGb 761 
(5 mg/animal, n=2) or an equivalent volume of PBS (n=2) was injected via a catheter in the 
carotid artery. Five minutes after bolus administration, lungs thoracic aortas were excised and 
immediately frozen in liquid nitrogen. The aortas were lyzed at 4°C by homogenization in a 
Ripa lysis buffer with a homogenizer (Potter S, B. Braun Biotech International, Melsungen, 
Germany). After sample centrifugation (14,000 rpm, 10 min, 4°C, two-times) 10 µl of the 
supernatant were further diluted and used for determination of protein content. The remaining 
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supernatant was diluted with Laemmli sample buffer (3x) and boiled at 95°C for 5 min. 
Samples were kept at -20°C until Western blot analysis. 
3.3.2 SDS-PAGE electrophoresis 
Proteins were separated by discontinuous SDS-polyacrylamid gel electrophoresis (SDS-
PAGE) according to Laemmli.121 SDS is a highly negative charged detergent, which binds to 
the hydrophobic parts of proteins and solubilises them. After denaturizing the proteins by 
reduction of disulfide bonds with ß-mercaptoethanol and boiling at 95°C for 5 min, the 
complexes of SDS with the denatured proteins have a large net negative charge that is related 
to the mass of the protein. Their migration velocity during the electrophoretic separation is 
now roughly proportional to the mass of the protein. Equal amounts of protein were loaded on 
gels and separated using the Mini-PROTEAN 3 electrophoresis module (Bio-Rad, Munich, 
Germany). Therefore, a discontinuous polyacrylamide gel was used consisting of separation 
and stacking gel. The concentration of RotiophoreseTM Gel 30 in the separating gel was 
adjusted for an optimal protein separation depending on the molecular weight of the proteins 
as shown in Table 3.1. Electrophoresis was carried out at 100 V for 21 min for stacking and 
200 V for 45 min for separation of the protein mixture. The molecular weight of proteins was 
determined by comparison with the prestained protein ladder (PageRulerTM, Fermentas, St. 
Leon-Rot, Germany). 
Table 3.1: Separation gel concentrations 
Protein Separation gel concentration 
eNOS, p-eNOS 7.5 % 
p-Raf, p-MEK 1/2, SH-PTP1 10 % 
ERK, p-ERK, Akt, p-Akt, MKP-1 12 % 
 
 
Separation gel 12%  Stacking gel 
Rotiophorese TM 
Gel 30 
40 %  Rotiophorese TM 
Gel 30 
17 % 
Tris (pH 8.8) 375 mM  Tris (pH 6.8) 125 mM 
SDS 0.1 %  SDS 0.1 % 
TEMED 0.1 %  TEMED 0.2 % 
APS 0.05 %  APS 0.1 % 
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Electrophoresis buffer   
Tris 4.9 mM     
Glycine 38 mM     
SDS 0.1 %     
H2O       
 
3.3.3 Electroblotting 
After protein separation by SDS-PAGE, proteins were transferred onto either PVDF or 
nitrocellulose membranes by electroblotting. Electroblotting also denoted as Western blotting 
is the most commonly used method to transfer proteins from a gel to a membrane.122 The 
protein transfer can be achieved either by placing the gel-membrane sandwich between 
absorbent paper soaked in transfer buffer (semi-dry transfer) or by complete immersion of a 
gel-membrane sandwich in a buffer (wet transfer). In the present work semi-dry transfer has 
been used for eNOS, Akt as well as ERK proteins whereas wet transfer has been performed 
by electroblotting MEK 1/2, Raf-1 and SHP-1. 
3.3.3.1 Semi-dry transfer 
Using a Transblot SD semidry transfer cell (Bio-Rad, Hercules, USA), the separated proteins 
were electrophoretically transferred to a PVDF membrane (Immobilon-P, Millipore, Bedford, 
MA, USA). Prior to blotting, the membrane was washed in methanol for 5 min and then 
incubated for at least 30 min in Anode buffer on a shaking platform. For semi-dry transfer, the 
gel-membrane sandwich is placed between carbon plate electrodes. Therefore, one sheet of 
thick blotting paper (Whatman Schleicher & Schüll, Dassel, Germany) was well soaked with 
Anode buffer and rolled onto the anode. Subsequently, the PVDF membrane and the gels 
were added. Finally the stack was covered with another sheet of thick blotting paper soaked 
with Cathode buffer. The transfer cell was closed and transfer was carried out at 15 V for 1 h. 
 
Anode buffer    Cathode buffer   
Tris 12 mM  Tris 12 mM 
CAPS 8 mM  CAPS 8 mM 
Methanol 15 %  SDS 0.1 % 
H2O    H2O   
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3.3.3.2 Wet transfer 
For the wet transfer, the sandwich assembly is placed in a buffer tank with platinum wire 
electrodes (Mini Trans-Blot Cell, Bio-Rad, Munich, Germany). A nitrocellulose membrane 
(HybondTM-ECLTM, Amersham Biosciences, Freiburg, Germany) was activated by soaking in 
tank buffer (1x) for at least 20 min. Transfer sandwich was assembled in a box containing 
tank buffer (1x) starting with a wetted pad. Subsequently, a soaked blotting paper, the gel 
followed by the membrane, a second blotting paper and a wetted pad were added. The 
sandwich assembly was mounted in the buffer tank, with the membrane facing the anode. 
Finally the cubette was filled up with tank buffer (1x) and transfer was performed at either 
25 V overnight or 100 V for 1.5 h, respectively. 
 
Tank buffer (5x)   Tank buffer (1x)  
Tris 125 mM  Blotting buffer 5x 20 % 
Glycine 200 mM  Methanol 20 % 
H2O    H2O   
 
3.3.4 Protein detection 
3.3.4.1 Specific protein staining 
Prior to the immunological detection of the relevant proteins, unspecific protein binding sites 
were blocked. Therefore, the membrane was incubated in Blotto 5% or BSA 5% for 2 h at 
room temperature. Afterwards, detection of the proteins was performed by incubating the 
membrane with the respective primary antibody at 4°C overnight. After four washing steps 
with PBS-T (each 5 min), the secondary antibody was added to the membrane for 1 h, 
followed by 4 additional washing steps. All steps regarding the incubation of the membrane 
were performed under gentle agitation. 
In order to visualize the proteins two different methods have been used depending on the 
labels of secondary antibodies. 
On the one hand, for horseradish peroxidase (HRP)-coupled secondary antibodies luminol 
was used as a substrate. The membrane was incubated in a 1:1 mixture of ECL solution A and 
B for 1 minute. The enzyme HRP catalyzes the oxidation of luminol in the presence of H2O2. 
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The reaction is displayed in Figure 3.1. The appearing luminescence was detected by 
exposure of the membrane to an X-ray film (Super RX, Fuji, Düsseldorf, Germany) and 
subsequently developed with a Curix 60 Developing system (Agfa-Gevaert AG, Cologne, 
Germany). 
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Figure 3.1  HRP-luminol reaction 
 
 
ECL solution A  ECL solution B 
Luminol 25 mM  H2O2 0.006 % 
p-Coumaric acid 0.396 mM  Tris (pH 8.5) 100 mM 
Tris (pH 8.5) 100 mM  H2O   
H2O       
 
On the other hand, antibodies directly labeled with infrared (IR) fluorophores,  
e.g. IRDyeTM800 and Alexa Fluor® 680 with emission at 800 and 700 nm, were applied. 
Protein bands of interest were detected using Odyssey imaging system (Li-Cor Biosciences, 
Lincoln, NE). After scanning the membrane with two-color detection, bands could be 
quantified using Odyssey software. 
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3.3.4.2 Antibodies 
Primary antibodies used for Western blot analysis are summarized in Table 3.2, while 
secondary antibodies are listed in Table 3.3. 
Table 3.2: Primary antibodies 
Antigen Isotype Dilution in Provider 
Actin mouse monoclonal 1:1,000; Blotto 1% Chemicon 
eNOS mouse monoclonal 1:1,000; BSA 5% BD Transduction 
Laboratories 
phospho-eNOS rabbit polyclonal 1:1,000; BSA 5% Cell Signaling 
Akt rabbit polyclonal 1:1,000; Blotto 5% Cell Signaling 
phospho-Akt mouse monoclonal 1:1,000; Blotto 5% Cell Signaling 
ERK rabbit polyclonal 1:1,000; Blotto 1% Cell Signaling 
phospho-ERK mouse monoclonal 1:1,000; Blotto 1% Cell Signaling 
phospho-MEK 1/2 rabbit polyclonal 1:200; BSA 5% Cell Signaling 
phospho-Raf-1 rabbit polyclonal 1:200; BSA 5% SantaCruz 
MKP-1 rabbit polyclonal 1:200; BSA 5% SantaCruz 
SH-PTP1 (SHP-1) rabbit polyclonal 1:200; BSA 5% SantaCruz 
phospho-Tyrosine mouse monoclonal 1:2000; BSA 5% Cell Signaling 
 
Table 3.3: Secondary antibodies 
Antibody Dilution in Provider 
Goat anti-mouse IgG1: HRP 1:1,000; Blotto 1% Biozol 
Goat anti-rabbit: HRP 1:1,000; Blotto 1% Dianova 
Alexa Fluor® 680 Goat anti-mouse IgG 1:10,000; Blotto 1% Molecular Probes 
Alexa Fluor® 680 Goat anti-rabbit IgG 1:10,000; Blotto 1% Molecular Probes 
IRDye 800CW Goat anti-mouse IgG 1:10,000; Blotto 1% LiCor Biosciences 
IRDyeTM 800 Goat anti-rabbit IgG 1:10,000; Blotto 1% Rockland 
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3.3.4.3 Unspecific protein staining of gels and membranes 
In order to ensure equal protein loading and blotting efficiency, gels as well as membranes 
were stained with Coomassie or Ponceau staining solution, respectively. 
After transfer, gels were incubated with Coomassie staining solution for 20 min. The dye 
penetrates the gel and stains all proteins without any specification. Afterwards, gels were 
extensively washed with Coomassie destaining solution for 60 min (6x, 10 min) until proteins 
appeared as blue bands. 
 
Coomassie staining solution  Coomassie destaining solution 
Coomassie blue G 0.3 %  Glacial acetic acid 10 % 
Glacial acetic acid 10 %  Ethanol 33 % 
Ethanol 45 %  H2O   
H2O       
 
Moreover, in order to ensure equal protein loading membranes were stained with Ponceau 
solution by agitation on a shaking platform for 5 min and were washed in water until the 
background disappeared. 
 
Ponceau solution   
Ponceau S 0.1 %     
Glacial acetic acid 5 %     
H2O       
 
3.3.5 Membrane stripping and reprobing 
In order to remove primary and secondary antibodies from the membrane (“stripping”), blots 
were incubated twice in stripping buffer for 15 min at room temperature. After extensive 
washing, stripping efficiency was confirmed by scanning the membrane to see if signals have 
been removed. Subsequently, the blot was re-blocked with Blotto 5% for 2 h and incubated 
with antibodies. 
 
Stripping buffer (pH 2.0)   
Glycine 25 mM     
SDS 1 %     
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3.4 Protein quantification 
In order to employ equal amounts of proteins in all samples, protein concentrations were 
determined using either Bicinchoninacid Assay (Pierce Assay) or Bradford Assay. After 
measurement protein concentration was adjusted by adding 1x sample buffer [Laemmli 
sample buffer (3x):Ripa lysis buffer=1:2]. 
3.4.1 Bicinchoninic acid (BCA) Protein Assay (Pierce Assay) 
Pierce Assay (BC Assay reagents, Interdim, Montulocon, France) was performed as described 
by Smith et al.123 10 µl protein samples were incubated with 200 µl BC Assay reagents for 
30 min at 37°C. Absorbance of the blue complex was measured photometrically at 550 nm 
(Tecan Sunrise Absorbance reader, TECAN, Crailsheim, Germany). Protein standards were 
obtained by diluting a stock solution of Bovine Serum Albumin (BSA, 2 mg/ml). Linear 
regression was used to determine the actual protein concentration of each sample. 
3.4.2 Bradford Assay 
Bradford Assay (Bradford solution, Bio-Rad, Munich, Germany) was performed as described 
by Bradford et al.124 It employes Coomassie Brillant Blue as a dye, which can bind to 
proteins. 10 µl protein samples were incubated with 190 µl Bradford solution (1:5 dilution in 
water) for 5 min. Thereafter, absorbance was measured photometrically at 592 nm (Tecan 
Sunrise Absorbance reader, TECAN, Crailsheim, Germany). Protein standards were achieved 
as described above (Pierce Assay, 3.4.1). 
3.5 Angiogenesis Assays 
Angiogenesis is the process of generating new blood vessels from an existing vasculature. 
Proliferation, migration, and tube formation of endothelial cells are the essential steps in this 
context. Since each of this steps can be a target for intervention, and each has been tested in 
vitro.125-127 Furthermore, the Chicken Chorioallantoic Membrane (CAM) Assay was 
performed. The CAM Assay is well established and widely used as a model to examine 
angiogenesis and anti-angiogenesis in vivo.126 
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3.5.1 Cell proliferation 
In order to assess the effects of EGb 761 on proliferation we have carried out two different 
assays, the Crystal Violet Staining Assay and the Trypan Blue Exclusion Assay. 
3.5.1.1 The Crystal Violet Staining Assay 
In the Crystal Violet Staining Assay, HMECs were seeded into flat-bottomed 96-well 
microplates by adding 100 µl of ECGM containing 1.5x103 cells. 24 h after incubation, cells 
in a reference plate were stained with crystal violet solution, serving as baseline (day 0). The 
cells in the remaining plates were treated with increasing concentrations of EGb 761. After an 
additional incubation (72 h), the medium was removed and cells were stained with 100 µl 
crystal violet solution for 10 min at room temperature. After washing five times with distilled 
water, bound dye was solubilized by addition of 100 µl dissolving buffer to each well. The 
absorbance was measured at 540 nm in a plate-reading photometer (SPECTRAFluor Plus; 
Tecan, Crailsheim, Germany). 
 
Crystal violet solution  Dissolving buffer 
Crystal violet 0.5 %  Sodium citrate 0.1 M 50 % 
Methanol 20 %  Ethanol 50 % 
H2O       
 
3.5.1.2 Direct counting of viable cells 
HMECs were seeded at a density of 1x105 cells/well in six-well plates. Subsequently, cells 
were stimulated with increasing concentrations of EGb 761 for 48 or 72 h. Afterwards, cells 
were trypsinized and the cell concentration as well as percentage of viable cells was 
determined by a 0.4% trypan blue solution using a Vi-CellTM cell viability analyzer (Beckman 
Coulter, Krefeld, Germany).  
3.5.2 Cell migration Assay (wound healing Assay) 
Confluent HUVEC monolayers were seeded in 24-well microplates and grown as monolayers 
on collagen G until they reach confluence. Afterwards, cells were scratched in a line across 
the well with the tip of a micropipette. The wounded monolayers were washed twice with 
PBS Ca2+/Mg2+ to remove floating cellular debris. Immediately, cells were refed with 
HUVEC growth medium. Endothelial cells were either left untreated, treated with EGb 761 
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(100 or 500 µg/ml, respectively) or pretreated with Na3VO4 (10 µM, 30 min) followed by 
stimulation with EGb 761. M199 media was used as negative control. After 16 h the area of 
cell-free wound was recorded using an imaging system (TILL Photonics GmbH, Gräfelfing, 
Germany) and a CCD-camera connected to an Axiovert 200 microscope (Zeiss, Oberkochen, 
Germany). 
The images were analyzed by a specifically designed software (S.CO LifeScience, Garching, 
Germany) as displayed in figure 3.2. Migration was expressed as the ratio of pixels covered 
by cells (yellow) and the number of pixels in the wound area (gray). 
A B C
 
figure 3.2  Quantitative evaluation of S.CO LifeSciences 
A, Cells stimulated with HUVEC growth medium. B, Cells treated with EGb 761 (100 µg/ml, 
16 h). C, HUVECs starved with M199 for a periode of 16 h. The uncovered area is displayed in 
gray, whereas the cell-covered area is highlighted in yellow. 
3.5.3 Tube formation 
In order to investigate the effects on the formation of capillary-like structures by HMECs, the 
surface of ibidi µ-slides (18-well, ibidi GmbH, Munich, Germany) was coated with BD 
Matrigel™ Matrix Growth Factor Reduced (GFR) (BD Biosciences, Heidelberg, Germany). 
MatrigelTM matrix is a solubilised basement membrane preparation extracted from EHS 
mouse sarcoma. By the time cells are cultured on MatrigelTM matrix, they will behave as they 
do in vivo. For this purpose, prior to preparation of gel, the BD Matrigel™ Matrix was thawed 
at 4°C overnight and kept on ice until use. 19 µl of MatrigelTM were added to each well of an 
ibidi slide using precooled pipettes, and MatrigelTM was allowed to polymerize at 37°C for 
30 min. Afterwards, the gels were overlaid with 30 µl ECGM containing 1x104 HMECs. 
Endothelial cells were either left untreated or treated with EGb 761 (100 or 500 µg/ml, 
respectively) for 16 h. Finally, cells were photographed using an imaging system (TILL 
Photonics, Gräfelfing, Germany) and a CCD-camera connected to an Axiovert 200 
microscope (Zeiss, Oberkochen, Germany). 
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3.5.4 The chorioallantoic membrane (CAM) Assay 
The CAM Assay was kindly performed by Johanna Liebl (Ludwig-Maximilians-University of 
Munich, Department of Pharmacy – Centre of Drug Research). Briefly, fertilized White 
Leghorn chicken eggs from Lohmann Tierzucht (Cuxhaven, Germany) were incubated at 
37°C at constant humidity for 72 h. Afterwards, fertilized eggs were cleaned with 70% 
ethanol before transferring the entire egg contents into a plastic culture dish with a size of 
100 mm (whole embryo culture). The eggs were returned to the incubator for further 72 h, 
during that time the CAM develops. CAMs were covered with sterile hydroxyethylcellulose 
discs loaded with either FGF (1 ng/disc) or combinations of EGb 761 (1.25, 2.5, and 
3.75 µg/disc, respectively) and FGF (1 ng/disc). The next day the vascular structure in the 
CAM was visualized using a stereomicroscope and a CCD camera (Olympus, Munich, 
Germany). 
3.6 Transfection of cells 
Transfection describes the introduction of genetic material into cultured mammalian cells. In 
these experiments genetic material (such as plasmid DNA or siRNA constructs) can be 
transfected using calcium phosphate, electroporation, lipofection or magnetofection. 
In order to silence the expression of SHP-1 genes human umbilical vein endothelial cells 
(HUVECs) were transiently transfected by electroporation with the  
Nucleofector™ II device (Amaxa, Cologne, Germany) employing the HUVEC Nucleofector® 
Kit (Amaxa, Cologne, Germany). Two On-TARGETplus Individual Duplexes were used as 
SHP-1 siRNA and were purchased from Dharmacon (Lafayette, CO, USA). Sence as well as 
antisence sequences are displayed in Table 3.4. The receipt siRNA was resuspended in 
Dharmacon 1x siRNA buffer, aliquoted and stored at -80°C. The concentration of siRNA was 
verified using a NanoDrop (Wilmington, DE, USA). 
Experimental procedure 
For each transfection, 2x106 HUVECs from passage three were combined with 100 µl 
HUVEC Nucleofector Solution and 1.5 µg siRNA Duplex J-009778-09 and 1.5 µg siRNA 
Duplex J-009778-09, respectively. The mixture of cells and RNA was transferred to an amaxa 
certified cuvette and transfection was performed using the program A-034. Afterwards, 900 µl 
of prewarmed culture medium was added to the cuvette. Cells were immediately seeded in 
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96-well (1x104 cells) or 6-well (5x105 cells) plates, cultured at 37°C, 5% CO2. Transiently 
transfected cells were used for crystal violet staining assays 24 h after transfection. 
Concurrently, HUVECs were transfected with On-TARGETplus siCONTROL Non-targeting 
siRNA (Dharmacon, Lafayette, CO, USA) using as transfection control. 
Table 3.4 SHP-1 siRNA sequences and Non-targeting siRNA sequence 
ON-TARGETplus Duplex SHP-1 siRNA 
Sense Sequence GGAACAAAUGCGUCCCAUAUU J-009778-09 
Antisense Sequence 5’-PUAUGGGACGCAUUUGUUCCUU 
Sense Sequence AUACAAACUCCGUACCUUAUU J-009778-10 
Antisense Sequence 5’-PUAAGGUACGGAGUUUGUAUUU 
 
 
ON-TARGETplus siCONTROL Non-targeting siRNA 
D-001810-01 Sequence 5’-UGGUUUACAUGUCGACUAA-3’ 
 
3.7 Raf-1 Kinase Assay 
In order to determine Raf-1 dependent phosphotransferase activity we used the nonradioactive 
Raf-1 Kinase Assay Kit (Upstate, Lake Placid, NY, USA) according to the manufacturer’s 
instructions. This kit measures the phosphotransferase activity of Raf-1 via phosphorylation 
of recombinant inactive MEK 1. 
The Raf-1 kinase cascade reaction is displayed in figure 3.3. Once phosphorylated by active 
Raf-1, MEK 1 can be determined by Western blot analysis as a parameter for Raf-1 kinase 
activity. The recombinant human MEK 1 is a fusion protein expressed in E. coli and contains 
both a N-terminal GST-tag and a C-terminal His6 tag. Recombinant MEK has a molecular 
weight of 71 kDa whereas endogen MEK 1 has a molecular weight of 45 kDa. 
MEK1, inactive + ATP Active MEK1 + ADP
Active Raf-1, 30°C, 30 min
 
figure 3.3  Raf-1 Kinase cascade reaction 
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Experimental procedure 
Briefly, HUVECs were cultured in 100 mm dishes and treated as indicated in the respective 
figure legend. Subsequently, cells were washed with ice-cold PBS, lyzed with Kinase lysis 
buffer, homogenized and centrifuged (16,000 rpm, 10 min, 4°C). Supernatants were used for 
protein determination (Bradford Assay, 3.4.2). Afterwards, 500 μg of protein in each cell 
lysate were incubated with 1 µg inactive MEK 1 substrate as well as the supplied Mg2+/ATP 
cocktail (75 mM and 500 mM, respectively) at 30°C for 30 min in a shaking incubator. At the 
same time 0.1 µg Raf-1 (truncated, active) was incubated with aforementioned reaction mix 
as positive control. Afterwards, Laemmli sample buffer was added and the samples were 
heated at 95°C for 5 min. The phosphorylated MEK 1 in the reaction mixture was detected by 
Western blot analysis with rabbit polyclonal phospho-MEK 1/2 (Ser217/221,  
Cell Signaling/New England Biolabs, Frankfurt/Main, Germany). 
 
Assay Dilution Buffer I (ADBI, pH 7.2)  
MOPS 20 mM     
ß-glycerophosphate 25 mM     
EGTA 5 mM     
add before use:       
activated Na3VO4 1 mM     
DTT 1 mM     
 
Buffer A  Kinase lysis buffer 
Tris 50 mM  M-Per   
EDTA 1 mM  add before use:   
EGTA 1 mM  CompleteTM 8 % 
ß-mercaptoethanol 0.1 %  PMSF 2 mM 
Triton X-100 1 %  activated Na3VO4 2 mM 
NaF 50 mM  NaF 2 mM 
Na4P2O7 5 mM  Na4P2O7 5 mM 
C3H5(OH)2PO4Na2 10 mM  C3H5(OH)2PO4Na2 4 mM 
add before use:       
CompleteTM 4 %     
PMSF 0.1 mM     
activated Na3VO4 0.5 mM     
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3.8 cAMP Assay 
The cAMP Assay consists of two parts: the accumulation of cAMP in intact cells and the 
determination of cAMP. The latter was studied by an enzyme-linked immunosorbant assay 
(ELISA) kindly performed by Dr. Hermann Ammer (Professor of Clinical Pharmacology, 
Department of Veterinary Sciences, University of Munich). 
Experimental procedure 
Accumulation of cAMP in intact HMECs was determined as follows: HMECs were seeded in 
24-well plates and grown as monolayer until 90% confluence. Immediately before 
stimulation, cells were washed three times with 1 ml/well pre-warmed DMEM containing 
10 mM HEPES (pH 7.4) and 0.01% BSA. Subsequently, cells were stimulated in total volume 
of 250 µl with EGb 761 or a combination of EGb 761 and 10 µM forskolin. Accumulation of 
cAMP was allowed for 30 min at 37°C and was terminated by the addition of 750 µl of ice-
cold HCl 50 mM. The amount of cAMP generated was determined in the supernatants by 
enzyme-linked immunosorbant assay after acetylation of the samples. 
3.9 Phosphatase-Assays 
A phosphatase is an enzyme that removes a phosphate group from its substrate. Protein 
phosphatases can be subdivided based upon their substrate specificity into two main classes: 
1) those that remove phosphate from proteins or peptides containing phosphoserine or 
phosphothreonine, and 2) those that remove phosphate from proteins or peptides containing 
phosphotyrosine. Members of each group have been investigated. In detail PP2A, PP2B and 
PP2C which are serine/threonine phosphatases as well as SHP-1 which is a tyrosine 
phosphatase were evaluated. 
3.9.1 Serine/Threonine Phosphatase-Assay 
In order to measure serine/threonine phosphatase activity we used the non-radioactive, 
molybdate dye-based phosphatase Assay kit (Promega, Mannheim, Germany) according to 
the manufacturer’s instructions. This serine/threonine phosphatase Assay system contains the 
chemically synthesized phosphopeptide, RRA(pT)VA. This peptide substrate is compatible 
with several serine/threonine phosphatases such as the protein phosphatases 2A, 2B and 2C. 
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However, the supplied phosphopeptide is a poor substrate for Protein Phosphatase 1 because 
of its more stringent structural requirements. The system allows the use of a variety of buffer 
conditions adjusted to the specific phosphatase and determines the amount of free phosphate 
generated in a reaction by measuring the absorbance of a molybdate:malachite 
green:phosphate complex. 
Experimental procedure 
Briefly, HMEC-1 were pre-incubated with EGb 761 (500 µg/ml, 30 min) and subsequently 
exposed to FGF (5 ng/ml, 30 min). Afterwards, cells were washed with PBS and lyzed with 
Phosphatase lysis buffer. Cells were scraped off, centrifuged (14,000 rpm, 10 min, 4°C), and 
supernatants were passed through the supplied Sephadex G-25 Spin column to remove free 
phosphate. Aliquots of the centrifuged effluent were Assayed for protein content using the 
Pierce Assay (3.4.1). The standard Assay was performed in PP2A, PP2B, or PP2C Assay 
buffer, respectively, containing 100 μM phosphoprotein RRA(pT)VA. Reactions were started 
by the addition of 5 µg samples and conducted for 30 min at 37°C. Reactions were terminated 
by the addition of 50 µl molybdate dye-additive mixture and color was developed by 
incubating the mixture for 30 min at room temperature before reading the plate at 600 nm 
(Tecan Sunrise Absorbance reader, TECAN, Crailsheim, Germany). 
 
Phosphatases lysis buffer 
(pH 7.4) 
 PP2A Assay buffer (pH 7.2) 
HEPES 20 mM  Imidazole 50 mM 
Glycerol 10 %  EGTA 0.2 mM 
Nonidet P-40 0.1 %  ß-mercaptoethanol 0.02 % 
EGTA 1 mM  BSA 0.1 mg/ml
MgCl2 0.1 mM     
ß-mercaptoethanol 30 mM     
add before use:       
PMSF 1 mM     
CompleteTM 4 %     
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PP2B Assay buffer (pH 7.2)  PP2C Assay buffer (pH 7.2) 
Imidazole 50 mM  Imidazole 50 mM 
EGTA 0.2 mM  EGTA 0.2 mM 
ß-mercaptoethanol 0.02 %  ß-mercaptoethanol 0.02 % 
MgCl2 10 mM  MgCl2 5 mM 
NiCl2 1 mM  BSA 0.1 mg/ml
Calmodulin 50 µg/ml     
 
3.9.2 SHP-1 Phosphatase-Assay 
SHP-1, also denoted as SH-PTP1 and PTPN6, is a SH2 domain-containing tyrosine 
phosphatase. This phosphatase plays an essential role in negative regulation of ERK activity 
and angiogenesis. Its activity was measured by immunoprecipitation of SHP-1 followed by 
PTP Assay using para-Nitrophenyl phosphate (p-NPP; Sigma, Taufkirchen, Germany) as an 
artificial substrate. p-NPP is dephosphorylated by SHP-1 to p-Nitrophenol following 
conversion to p-Nitrophenylene anion (Figure 3.4). 
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Figure 3.4 Dephosphorylation of p-NPP by SHP-1 
 
Experimental procedure 
In brief, HUVECs were cultivated in 100 mm dishes and treated as indicated in the respective 
figure legend. Thereafter, cells were washed with ice-cold PBS and lyzed with 500 µl SHP-1 
lysis buffer. Cells were homogenized and centrifuged (16,000 rpm, 10 min, 4°C). Protein 
concentrations from supernatants were determined using Pierce Assay (3.4.1). Equal amounts 
of protein were immunoprecipitated. Therefore, 500 to 1,000 µg of proteins per sample were 
incubated with 10 µg SHP-1 antibody for 2 h at 4°C under gentle agitation. Subsequently, 
protein-antibody solution was mixed with 100 µl µMACS protein G microbeads (Miltenyi 
Biotec; Bergisch Gladbach, Germany) and incubated for 30 min on ice. Immune complexes 
were transferred to µColumns using a µMACS Separation Unit and washed twice with SHP-1 
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lysis buffer without Triton X-100 and without deoxycholat. Immune complexes were 
incubated in the SHP-1 PPase Assay buffer for 1 h at 37°C, and subsequently transferred to 
96-well plates. The reaction was stopped by addition of 3 µl NaOH (1 N). The amount of 
phosphate release was determined by measuring the absorbance at 405 nm (SPECTRAFluor 
Plus; TECAN, Crailsheim, Germany). In order to verify phosphatase activity immune 
complexes were incubated with 100 µl Na3VO4 (10 mM) for 30 min at 37°C and 100 µl  
SHP-1 PPase Assay buffer containing Na3VO4 (10 mM) for 60 min at 37°C. 
 
SHP-1 lysis buffer (pH 7.35)  SHP-1 PPase Assay buffer (pH 5) 
Tris-HCl 20 mM  HEPES 20 mM 
EDTA 1 mM  NaCl 100 mM 
add before use:    MgCl2 5 mM 
Pefabloc® SC 1 mM  add before use:   
Leupeptin* ½ 
H2SO4 
1 µM  p-NPP 100 mM 
Pepstatin A 1 µM     
Aprotinin 1 µM     
Triton X-100 1.0 %     
Deoxycholat 0.5 %     
 
3.10 Immunocytochemistry and confocal laser scanning microscopy 
Immunocytochemistry was performed to determine changes in localization of phospho-eNOS 
protein levels. Confocal Laser Scanning Microscopy (CLSM) has been used as an optical 
imaging technique. 
Experimental procedure 
EA.hy926 cells were cultured on collagen A-coated glass cover slips (diameter: 12 mm) until 
confluence and treated as indicated. After treatment, cells were washed with PBS Ca2+/Mg2+ 
and fixed with 3% formaldehyde (Sigma, Taufkirchen, Germany) for 15 min. Subsequently, 
cells were permeabilized with 0.2% Triton X-100 (Sigma, Taufkirchen, Germany) for 2 min. 
Following further washing steps with PBS Ca2+/Mg2+, unspecific binding was blocked by 
incubation with 0.2 % bovine serum albumin (BSA) solution for 60 min. Cells were incubated 
with the primary antibody [anti-phospho eNOS (Ser 1177), Cell Signaling, 1:100 in 0.2% 
BSA solution] for 1 h. As secondary antibody, AlexaFluor® 633 Goat anti-rabbit antibody 
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(Molecular Probes, Karlsruhe, Germany) was used at a dilution of 1:400 for 45 min. Finally, 
the cover slips were embedded in PermaFluor® Aqueous Mounting Medium (Beckman 
Coulter, Krefeld, Germany) and put onto glass objective slides. Images were obtained with a 
Zeiss LSM 510 Meta confocal laser scanning microscope (Zeiss, Oberkochen, Germany). 
 
Fixation solution  Permeabilisation buffer 
Formalin 3 %  Triton X-100 0.2 % 
PBS Ca2+/Mg2+    PBS   
 
Blocking buffer   
BSA 0.2 %     
PBS       
 
3.11 Luciferase Reporter Gene Assay 
Firefly luciferase is widely used as a reporter to study gene expression. Light is produced by 
converting the chemical energy of luciferin oxidation through an electron transition, forming 
the product molecule oxyluciferin. The enzyme catalyzes the luciferin oxidation using ATP 
and Mg2+ as co-substrates. The generated flash of light can be conveniently measured on a 
luminometer. Figure 3.5 displays the bioluminescent reaction. 
N
SN
SOH COOH
N
SN
SO O
+ ATP + O2
luciferase
Mg2+
+ AMP + PPi + CO2 + Licht
Luciferin
Oxyluciferin  
Figure 3.5  Bioluminescent reaction catalyzed by firefly luciferase. 
 
eNOS promoter activity 
Luciferase Reporter Gene Assay (Luciferase Assay system, Promega, Mannheim, Germany) 
was used to measure the regulatory potential of human eNOS promoter. This has been done 
by linking the human eNOS promoter sequence to the comfortably detectable reporter gene 
encoding for firefly luciferase. 
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Experimental procedure 
For Luciferase Reporter Gene Assay experiments stably transfected EA.hy926 cells were 
used. Endothelial cells were seeded in 24-well plates at a density of 75x104 cells per well. 
Confluent cells were stimulated with increasing concentrations of EGb 761 (10 to 500 µg/ml) 
for 24 h. Subsequently, cells were washed once with ice-cold PBS and lyzed with 150 µl 
Luciferase Cell Culture Lysis Reagent (Luciferase Assay System, Promega, Mannheim, 
Germany). Following 10 min of incubation, cell lysates were centrifuged (6,000 g, 4°C, 
5 min). 20 µl of supernatant were recovered in luminometer tubes and adjusted to room 
temperature. Afterwards, the luminometer (AutoLumatPlus, Berthold Technologies, Bad 
Wildbad Germany) was programmed to perform a 2-second measurement delay followed by a 
8-second measurement read for luciferase activity. The luminometer injector was primed at 
least three times with Luciferase Assay Reagent (Luciferase Assay System, Promega, 
Mannheim, Germany). Luminometer tubes were placed in the luminometer and reaction was 
initiated by injecting 70 µl of Luciferase Assay Reagent into each tube. 
3.12  [14C]L-arginine/[14C]L-citrulline conversion Assay 
The arginine-citrulline conversion Assay detects the conversion of radio-labelled  
[14C]L-arginine to radio-labelled [14C]L-citrulline. This reaction, as displayed in Figure 3.6, is 
catalyzed by endothelial nitric oxide synthase (eNOS). The conversion of L-arginine leads to 
equimolar amounts of NO as well as L-citrullin. The amount of [14C]L-citrulline can be used 
indirectly as a parameter of NO production. 
NH2
NH
N
H
NH2
COOH
NH2
N
N
H
NH2
COOH
OH
NH2
O
N
H
NH2
COOH +NO
L-arginine
L-citrulline
L-N-hydroxyarginine
O2
 
Figure 3.6  Conversion of L-arginine to L-citrulline 
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Experimental procedure 
EA.hy926 cells were seeded in 6-well plates with a concentration of 0.5x106 cells/well. 
Confluent cells were stimulated with increasing concentrations of EGb 761 (10 to 100 µg/ml) 
for 48 h. Cells were washed and kept in 1 ml HEPES buffer for 45 min at 37°C before 
addition of 0.32 µM [14C]L-arginine (313 mCi/mM, Perkin Elmer, Massachusetts, USA) and 
1 µM A23187. After incubation for 25 min at 37°C cells were lyzed with ice-cold ethanol 
(96%). Lysates were extracted with water. The supernatants were dried under vacuum. The 
extract was resolved in water/methanol mixture (1:1) and spotted on a thin layer 
chromatography plate (Polygram® Sil N-HR, Macherey-Nagel, Düren, Germany).  
[14C]L-arginine was separated from [14C]L-citrulline using the mobil solvent system 
water/chloroform/methanol/ammonium hydroxide. The chromatography plates were dried and 
analyzed using a phosphorimager (Fujifilm BAS-1500). 
 
HEPES buffer (pH 7.4)  Mobile phase 
HEPES 2 mM  Methanol 45 % 
NaCl 29 mM  Ammonia 25% 20 % 
KCl 1 mM  Chloroform 5 % 
MgSO4 0.2 mM  H2O 10 % 
Glucose 2 mM     
CaCl 0.3 mM     
H2O       
 
3.13 Rat Thoracic Aortic Ring Assay 
Rat Thoracic Aortic Ring Assay was kindly performed by Dr. Egon Koch (Preclinical 
Research, Dr. Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany). Briefly, thoracic 
aortas from male Sprague-Dawley rats (Janvier, Le Genest, France) were immediately 
removed after decapitation and placed in Tyrode salt solution (mM: NaCl 118.2; NaHCO3 
24.8; KCl 4.6; CaCl2 2.5; MgSO4, 1.2; KH2PO4 1.2; glucose 10). After removal of fat and 
connective tissue, vessels were cut into 4 mm long rings. The rings were mounted on stainless 
steel hooks in an organ chamber (Hugo Sachs, Hugstetten, Germany) and maintained at 37°C 
equilibrated with 95% O2 and 5% CO2. Isometric tension studies were performed using force 
transducers (Statham UC2, Hugo Sachs, Hugstetten, Germany) connected to a four-channel 
recorder (Lineacorder, Graphtec). Integrity of vasomotion was tested by repetitive  
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pre-contraction with phenylephrine (PE, 0.15 µg/ml). Endothelial function was evaluated by 
vascular relaxation to acetylcholine (ACh, 0.25 µg/ml) after PE-induced contraction. 
Vasodilatory effects of EGb 761 were studied by cumulative addition of extract 
concentrations from 6.4 up to 200 μg/ml (n=12) at the plateau of the PE-induced contraction. 
Finally, endothelial-dependent and -independent relaxation was tested by subsequent 
application of ACh (0.25 µg/ml) and papaverine (Pap; 37.6 µg/ml), respectively. As a solvent 
control, respective cumulative concentrations of DMSO were applied (n=4). Endothelial-
independent relaxation was studied by using endothelium-denuded aortic rings (n=8). 
3.14 In Vivo Blood Pressure Measurement 
In vivo Blood Pressure Measurement was kindly performed by Andreas Hartkorn (Ludwig-
Maximilians-University of Munich, Department of Pharmacy – Centre of Drug Research). In 
brief, male Sprague-Dawley rats (180–220 g) were purchased from Charles River Wiga 
GmbH (Sulzfeld, Germany). The animals had free access to chow (Sniff, Soest, Germany) 
and water up to the time of experiments. All animals received human care according to the 
criteria outlined in the “Guide for the Care and Use of Laboratory Animals” published by the 
National Institute of Health (NIH publication 86-23 revised 1985). Studies were performed 
with the permission of the government authorities. Animals were anesthetized with a mixture 
of midazolam/fentanyl solution (2.0/0.005 mg/kg, i.p.) and kept continuously anesthetized by 
inhalation of isoflurane (1.3%). Blood pressure was continuously monitored by a catheter in 
the carotid artery. One group of animals served as solvent control. Another group received an 
i.v. injection of EGb 761 (5 mg/animal), whereas a third group received an additional i.v. 
injection of L-NAME (4 mg/animal, Cayman Chemical Company, Michigan, USA) 30 min 
prior to the EGb 761 application. 
3.15 Flow cytometry (FACS) 
Flow cytometry is a technique for counting, examining, and sorting microscopic particles 
suspended in a stream of fluid. It allows simultaneous multiparametric analysis of the physical 
and/or chemical characteristics of single cells flowing through a focused laser beam. Each 
suspended particle passing through the beam scatters the light in some way, and fluorescent 
chemicals found in the particle or attached to the particle may be excited into emitting light at 
a lower frequency than the light source. This combination of scattered and fluorescent light is 
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picked up by the detectors and gives information about size, granularity and stain intensity of 
each individual particle. Flow cytometry has been used for the analysis of cell cycle and 
apoptosis. All measurements were performed on a FACSCalibur (Becton Dickinson, 
Heidelberg, Germany), where cells were illuminated by a blue argon laser (488 nm). 
Cell cycle analysis and quantification of apoptosis rate 
One of the most widely used techniques for cell cycle analysis and quantification of apoptosis 
rate is the method described by Nicoletti et al.128 In this technique propidium iodide (PI) is 
used as a red fluorescent dye which binds to DNA and RNA by intercalating between the 
bases. When bound to nucleic acids, its absorption and emission wavelengths are 535 and 
617 nm, respectively. Cells with an intact membrane are impermeable to PI. Therefore, cells 
are permeabilised in a hypotonic buffer that contains PI. The whole DNA content of cells is 
stained and the red fluorescence is measured by flow cytometry giving information about cell 
cycle phase and apoptosis.  
The cell cycle consists of four distinct phases: G1/G0 phase, S phase, G2 phase (collectively 
known as interphase) and M phase. Most cells of normal untreated cell populations are in 
G1/G0 phase with single DNA content and emit a homogenous fluorescence after binding of 
PI to DNA. Cells in G2/M phase with a double DNA content peak at higher fluorescence 
intensity whereas cells in S phase appear between the G1/G0 and G2/M peaks. Apoptotic cells 
with DNA fragments containing hypodiploid DNA have lower fluorescence intensity, and 
thus appear “left” to the G1/G0 peak in the histogram. The four distinct phases of the cell cycle 
and their histogram plot are displayed in Figure 3.7. 
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Figure 3.7  The cell cycle. 
A: The cell cycle with its four distinct phases. B: A histogram plot of the cell cycle phases. 
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Experimental procedure 
HMECs were seeded in 6-well plates and either left untreated or stimulated with increasing 
concentrations of EGb 761 (10 to 500 µg/ml). After 48 h cells were harvested by trypsination. 
Cells were washed three-times with PBS and centrifugated at 600 g and 4°C for 10 min. 
Subsequently, cells were incubated in assay buffer [hypotonic fluorochrome solution (HFS) 
buffer] containing PI at 4°C overnight and analyzed by flow cytometry on a FACSCalibur. 
The logarithmic mode of FL2 detector (585 nm) was recorded and the instruments settings 
were adjusted in each experiment. A histogram plot of untreated cells (control) and EGb 761 
treated cells (500 µg/ml) is displayed in Figure 3.8. 
 
FACS buffer (pH 7.37)  HFS buffer 
NaCl 138.95 mM  Propidium iodide 75 nM 
K2HPO4 1.91 mM  Sodium citrate 0.1 % 
NaH2PO4 16.55 mM  Triton X-100 0.1 % 
KCl 3.76 mM  PBS   
LiCl 10.14 mM     
NaN3 3.08 mM     
Na2EDTA 0.97 mM     
H2O       
 
 
101100 102 103 104
0
100
75
25
50
A
0
100
75
25
50
101100 102 103 104
B
co
un
ts
co
un
ts
FL2-H FL2-H
apoptotic cells apoptotic cells
 
Figure 3.8  The Histogramm Plot. 
Representative examples of either control cells (A) or EGb 761-treated cells (B) are displayed. 
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3.16 Real-time RT-PCR 
Real-time RT-PCR is a technique used to quantify different mRNA amounts of certain genes. 
Previous to this technique are two steps: the RNA isolation as well as the translation of RNA 
into cDNA also denoted as Reverse Transcription. Following these two steps the 
amplification of cDNA with continuous measurement of DNA amount was performed using a 
7500 Real-time PCR System (Applied Biosystems, Foster City, CA, USA). Data are collected 
throughout the entire process. For this reason, fluorophore-containing DNA probes, such as 
TaqMan® probes, are used to measure the amount of amplified product in real time. TaqMan® 
probe contains a reporter dye at the 5’ end of the probe and a quencher dye at the 3’ end of the 
probe. During the PCR reaction the 5’ nuclease activity of AmpliTaq Gold® DNA Polymerase 
cleaves the TaqMan® probe. This cleavage of the probe separates the reporter dye and the 
quencher dye, which results in increased fluorescence of the reporter (Figure 3.9). 
Accumulation of PCR products is detected directly by monitoring the increase in fluorescence 
intensity of the reporter dye. 
PCR Primer
DNA template
3‘
5‘
5‘
3‘
5‘
5‘
Reporter Quencher
 
Figure 3.9  Cleavage of TaqMan®-Probe by AmpliTaq Gold® DNA Polymerase. 
 
3.16.1 Isolation of RNA 
Total RNA was extracted using the RNeasy mini Kit (Qiagen GmbH, Hilden, Germany) 
according to the instruction manual. Cells were cultured in 6-well plates and were treated as 
indicated. Thereafter, cells were lyzed and homogenized in the presence of a highly 
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denaturating guanidine isothiocyanate (GITC)-containing buffer (Buffer RLT). This buffer 
immediately inactivates ribonucleases (RNases) to ensure isolation of intact RNA. Samples 
were loaded onto a QIAshredder Spin Column and spun down (14,000 rpm, 2 min, RT). 
Samples were mixed with ethanol to provide appropriate binding conditions for RNA and 
transferred onto RNeasy mini Spin Columns. All other cellular components were removed by 
washing with two different washing buffers (Buffer RW1 and RPE). Since the method of real-
time PCR is accident-sensitive to very small amounts of DNA-contamination, DNA-digestion 
was performed during the isolation procedure (RNase Free DNase Set, Qiagen, Hilden, 
Germany). The purified RNA was eluted from the column with 50 µl of RNase free water 
under low salt conditions. Samples were taken for quantification of total RNA, verification of 
RNA integrity and stored at -85°C until used for reverse transcription. 
RNA concentration was determined by measuring the absorption at 260 nm (A260) and 
280 nm (A280) (NanoDrop, Wilmington, DE, USA). Integrity of isolated RNA was checked 
subjecting 1 µg of total RNA to agarose gel electrophoresis, ethidium bromide staining and 
densitometric analysis (Kodak Image Station, Kodak, Rochester, USA). The intensity ratio of 
ribosomal 28S and 18S RNA was used for evaluation of RNA integrity. 
3.16.2 Reverse Transcription 
Reverse transcription was performed with the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, DA, USA) according to the users’ manual. This 
Reverse Transcription Kit allows the quantitative conversion of up to 2 μg (for a 20-μl 
reaction) of total RNA to single-stranded cDNA. Reverse transcription was carried out in a 
Primus 25 advanced® (Peqlab Biotechnologie GmbH, Erlangen Germany) using the cycling 
protocol displayed in Table 3.5. cDNA was aliquoted and stored at -20°C until used for real-
time RT-PCR. 
Table 3.5 Reverse transcription cycling protocol 
Step Primer extension cDNA synthesis Termination 
Time 10 min 120 min 5 sec 
Temperature 95°C 95°C 60°C 
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3.16.3 Real-time PCR with TaqMan® probes 
Primer and Probe 
All Primers and probes were designed with Primer Express 2.0 software (Applied 
Biosystems) and obtained from InvitrogenTM (Karlsruhe, Germany) or biomers.net (Ulm, 
Germany), respectively. The probe oligonucleotide sequence is labeled with the reporter dye 
6-carboxyfluorescein (FAM) at the 5’ end and the quencher dye tetramethyl-6-
carboxyrhodamine (TAMRA) at the 3’ end. Sequences of forward as well as reverse primers 
and probe are displayed in Table 3.6. 
Table 3.6 Primer and Probe sequences 
MKP-1 (DUSP-6) 
forward human 5’-GACGCTCCTCTCTCAGTCCAA-3’ 
reverse human 5’-GGCGCTTTTCGAGGAAAAG-3’ 
probe human 6-Fam-TTCGGCGCAGAGAGACCCGG-Tamra 
 
GAPDH 
forward human 5’-GGGAAGGTGAAGGTCGGAGT-3’ 
reverse human 5’-TCCACTTTACCAGAGTTAAAAGCAG-3’ 
probe human 6-Fam-ACCAGGCGCCCAATACGACCAA-Tamra 
 
Experimental procedure 
Real-time RT-PCR was performed using the TaqMan® Universal PCR Master Mix, No 
AmpErase Ung (Applied Biosystems, Foster City, CA, USA) according to the manufactures 
instructions. In this method thermal cycling conditions as displayed in Table 3.7 have been 
used. In brief, 45% of the final mixture (20 µl) was provided by the cDNA sample, which 
contained between 10 and 100 ng cDNA. All samples were run in duplicates. Real time RT-
PCR was accomplished with 100 nM probe and 400 nM of each forward and reverse primer. 
Standard curves were constructed on a 1:5, 1:10, 1:50 and 1:100 dilution of total RNA. The 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was used as an internal 
housekeeping gene to normalize the MKP-1 data sets. Calculation of the mRNA content was 
performed with the new mathematical model for relative quantification of real time PCR 
products developed by Pfaffl et al.129 
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Table 3.7 Real-time RT-PCR thermal cycling conditions 
Step AmpliTaq Gold® 
Enzyme activation 
PCR 
Cycle (40-45 cycles) 
 Hold Denature Anneal/Extend 
Time 10 min 15 sec 1 min 
Temperature 95°C 95°C 60°C 
 
Product determination 
In order to check for primer dimers and secondary PCR products, all samples were separated 
by agarose gel electrophoresis. Therefore, ethidiumbromide agarose gels have been prepared. 
PCR products were supplemented with 6x blue/orange loading dye and loaded onto an 
agarose gel. Subsequently, electrophoresis has been performed with TBE buffer for 2 h  
at 100 V. Fluorescence of intercalated ethidiumbromide into the PCR products was visualized 
with a Kodak Image Station (Kodak, Rochester, USA) at 254 nm. 
 
TBE buffer  Agarose gel 
Tris 89 mM  Agarose 1.2 % 
Boric acid 89 mM  Ethidiumbromide 0.01 % 
EDTA 0.5 mM  TBE buffer   
H2O       
 
3.17 Statistical analysis 
All experiments were performed at least three times in duplicates unless otherwise noted in 
the respective figure legend. Data are expressed as mean ± SEM. Statistical analysis was 
performed with SigmaStat software version 3.1 (Aspire Software International). Samples 
were analyzed by Kryskal-Wallis One-Way Analysis of Variance on Ranks followed by 
Dunn’s Method or Student-Newman-Keuls post-hoc test, as appropriate (indicated in the 
figure legend). Differences between groups were considered significant if p≤0.05. 
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4.1 Endothelial nitric oxide production 
The standardized Ginkgo biloba extract EGb 761 exerts a beneficial role in the treatment of 
cardiovascular diseases.130-132 However, the underlying molecular mechanisms and signaling 
pathways have as yet remained widely unknown. Thus, we were interested in the modulation 
of nitric oxide (NO) generation by Ginkgo biloba extract. 
In principle there are two ways to increase NO production: induction of endothelial nitric 
oxide synthase (eNOS) expression and posttranscriptional activation of eNOS. The effects of 
EGb 761 on both ways were investigated. 
4.1.1 EGb 761 up-regulates eNOS promoter activity, eNOS protein expression, and 
eNOS activity 
In order to investigate the effects of EGb 761 on transcriptional regulation of NO generation, 
we performed an eNOS promoter activity assay. EA.hy926 cells, stably transfected with a 
3.6-kb human eNOS promoter fragment, were stimulated with increasing concentrations of 
EGb 761 (10 to 500 µg/ml). After the stimulation for 24 h eNOS promoter activity was 
concentration-dependently enhanced up to 1.4-fold (100 µg/ml, Figure 4.1). 
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Figure 4.1 EGb 761 increases eNOS promoter activity. 
Stably transfected EA.hy926 cells containing a 3.6-kb eNOS promoter driving a luciferase 
reporter gene were either kept untreated (co) or stimulated with increasing concentrations of 
EGb 761 (10 to 500 µg/ml) for 24 h. Cells were lyzed and analyzed for luciferase activity. Data 
are presented as mean ± SEM of 3 independent experiments. *≤0.05 vs. control, Kruskal-
Wallis One Way Analysis of Variance on Ranks (Dunn’s Method). 
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Furthermore, the influence of EGb 761 on eNOS protein expression was assessed by Western 
blot analysis. Stimulation with 500 µg/ml EGb 761 induced eNOS protein expression in 
EA.hy926 cells after 48 h (Figure 4.2). 
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Figure 4.2 EGb 761 enhances eNOS protein expression. 
EA.hy926 cells were either left untreated (co) or were treated with EGb 761 (50 to 500 µg/ml) 
for 48 h. Levels of eNOS (upper panel) and actin (lower panel) protein were determined by 
Western blot analysis. One representative blot out of 3 independent experiments is shown. 
After the same period of time (48 h), when eNOS expression was increased, NO production 
was measured indirectly using the [14C]L-arginine/[14C]L-citrulline conversion assay. As 
displayed in Figure 4.3 we detected an increase in [14C]L-citrulline production of 
approximately 1.5-fold after incubation with EGb 761 concentrations ranging between 10 to 
100 µg/ml. 
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Figure 4.3 EGb 761 up-regulates eNOS activity/[14C]L-citrulline production. 
eNOS activity was determined by [14C]L-arginine/[14C]L-citrulline conversion assay. Cells 
were either left untreated (co) or were treated with increasing concentrations (1 to 100 µg/ml) 
of EGb 761 for 48 h. A, Data are presented as mean ± SEM of 3 independent experiments. 
*≤0.05 vs. control, Kruskal-Wallis One Way Analysis of Variance on Ranks (Dunn’s Method).  
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4.1.2 EGb 761 promotes eNOS phosphorylation at Ser1177 
In addition to the long-term influence of EGb 761 on transcriptional regulation of eNOS, we 
evaluated whether eNOS is acutely activated in EA.hy926 cells. As displayed in Figure 4.4 a 
time course for eNOS phosphorylation at Ser1177 was performed. Ser1177 is a 
phosphorylation site important for eNOS activation.43 Indeed, EGb 761 (100 µg/ml) induced 
an eNOS phosphorylation reaching a maximum at 60 min. 
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Figure 4.4 EGb 761 increases eNOS phosphorylation at Ser1177. 
EA.hy926 cells were either left untreated (co) or were treated with EGb 761 (100 µg/ml) for 
indicated times. Levels of phospho-eNOS (Ser1177, upper panel) and total eNOS (lower panel) 
protein were determined by Western blot analysis. One representative blot out of 3 independent 
experiments is shown. The graph displays the signal intensities obtained by 
chemiluminescence evaluation. Bars represent the mean ± SEM of phospho-eNOS signals 
normalized by total eNOS signals. 
Furthermore, we investigated whether EGb 761 influences the intracellular distribution of 
phosphorylated eNOS by means of confocal microscopy. As seen in Figure 4.5, 
phosphorylated eNOS was rapidly translocated to the plasma membrane upon treatment with 
100 mg/ml EGb 761 for 15 min. 
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Figure 4.5 EGb 761 leads to a rapid translocation of phosphorylated eNOS to the plasma membrane. 
Representative photomicrographs are shown after immunofluorescent staining of EA.hy926 
cells. Fluorescence indicates phosphorylated eNOS protein. In contrast to untreated cells (1), 
cells receiving 100 µg/ml EGb 761 for 15 min (2 and 3) showed translocation of 
phosphorylated eNOS to the plasma membrane (arrows). 
4.1.3 Activation of eNOS via the PI3K/Akt pathway 
In order to analyze an involvement of protein kinase B/Akt in the phosphorylation of eNOS at 
Ser1177, we examined whether EGb 761 activates Akt by phosphorylation (Ser473). Akt 
phosphorylation was indeed found to be increased after EGb 761 exposure and occurred in a 
time-dependent manner (Figure 4.6). Maximum activation was achieved 60 min after 
treatment with EGb 100 µg/ml, closely approximating the time course of eNOS 
phosphorylation at Ser1177 (Figure 4.6). 
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Figure 4.6 EGb 761 increases Akt phosphorylation at Ser473. 
EA.hy926 cells were either left untreated (co) or were treated with EGb 761 (100 µg/ml) for 
indicated times. Levels of phospho-Akt (Ser473, upper panel) and total Akt (lower panel) 
protein were determined by Western blot analysis. One representative blot out of 3 independent 
experiments is shown. The graph displays the signal intensities obtained by 
chemiluminescence evaluation. Bars represent the mean ± SEM of phospho-Akt signals 
normalized by total Akt signals. 
To further investigate whether PI3K is involved in the EGb-mediated phosphorylation of 
eNOS, we incubated EA.hy926 cells with the PI3K-inhibitor wortmannin before exposure to 
EGb 761 (100 μg/ml). EGb 761-induced Akt phosphorylation was inhibited by wortmannin 
(Figure 4.7). 
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Figure 4.7 Wortmannin completely abolished EGb 761-induced phosphorylation of Akt. 
EA.hy926 cells were pre-treated with wortmannin (50 nM) for 30 min before EGb 761 
(100 μg/ml, 60 min). Levels of phospho-Akt and Akt protein level were determined by 
Western blot analysis. One representative blot out of 3 independent experiments is shown 
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Moreover, the inhibitor completely abolished EGb 761-induced phosphorylation of eNOS 
(Figure 4.8). These results demonstrate that the EGb 761-induced phosphorylation of eNOS at 
Ser1177 might be Akt-dependent. An alternative explanation would be the phosphorylation of 
eNOS by a different kinase downstream of PI3K. 
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Figure 4.8 EGb 761-induced phosphorylation of eNOS at Ser1177 is mediated by the PI3K/Akt pathway. 
EA.hy926 cells were pre-treated with wortmannin (50 nM) for 30 min before EGb 761 
(100 μg/ml, 60 min). Levels of phospho-Akt, Akt, phospho-eNOS, and eNOS protein were 
determined by Western blot analysis. One representative blot out of 3 independent experiments 
is shown. 
 
4.1.4 Vasorelaxant effect of EGb 761 on rat thoracic aortic rings 
EGb 761 (6.4 to 200 µg/ml) elicited dose-dependent relaxation of rat thoracic aortic rings 
with intact endothelium. Figure 4.9 A shows the reduced contraction of ring segments of rat 
thoracic aortas by EGb 761 at the plateau of the phenylephrine (PE)-induced contraction. 
Moreover, the subsequent application of acetylcholine (ACh) and papaverine (Pap) is 
displayed controlling endothelial-dependent and -independent vasorelaxation. The maximal 
relaxation of 50% was reached at a concentration of 200 µg/ml EGb 761 (Figure 4.9 B). In 
order to exclude any effects of cumulative concentrations of the solvent dimethyl sulfoxide 
(DMSO), pre-contracted rat thoracic aortic rings were exposed to DMSO 
(0.3 to 8.0 µl/20 ml). The result, displayed in Figure 4.9 C, assessed no effect of various 
DMSO concentrations on aortic ring relaxation. Furthermore, the vasorelaxant effect of 
EGb 761 was analyzed on aortic rings without any functional endothelium. Importantly, 
EGb 761 failed to produce relaxation in aortas without functional endothelium (Figure 4.9 D). 
This fact points to an involvement of NO in the endothelium-dependent vasorelaxation 
induced by EGb 761. 
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Figure 4.9 EGb 761 concentration-dependently induces relaxation of pre-contracted thoracic aortic rings. 
A, Relaxation of ring segments of rat thoracic aorta by cumulative addition from 6.4 up to 
200 μg/ml EGb 761 (n=12) at the plateau of the phenylephrine (PE)-induced contraction 
(0.15 µg/ml), followed by application of acetylcholine (ACh) (0.25 µg/ml) and papaverine 
(Pap; 37.6 µg/ml) to control endothelial-dependent and -independent vasorelaxation. 
B, Sigmoidal dose-response curve of aortic ring relaxation by EGb 761 expressed as 
percentage of the phenylephrine-induced contraction. Values are presented as mean ± SEM 
(n=12). C, Sigmoidal dose-response curve of aortic ring relaxation by DMSO expressed as 
percentage of the phenylephrine-induced contraction. Values are presented as mean ± SEM 
(n=4). D, Concentration-response curve of endothelium-denuded aortic rings to EGb 761 
expressed as percentage of the phenylephrine-induced contraction. Values are presented as 
mean ± SEM (n=8). The experiment was performed by Egon Koch (Preclinical Research, Dr. 
Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany). 
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4.1.5 EGb 761 reduces systolic blood pressure in rats via NO release 
In order to analyze the effect of EGb 761 on blood pressure, invasive blood pressure 
measurements were performed as shown in Figure 4.10. EGb 761 (5 mg/animal) significantly 
decreased systolic blood pressure. After 5 min the systolic blood pressure decreased from 
120 mmHg to 65 mmHg. In order to causally link the blood pressure alterations to an 
enhanced NO release, animals were pretreated with the eNOS inhibitor L-NAME (4 
mg/animal; 30 min). Pre-treatment of animals with L-NAME completely prevented the 
reduction of blood pressure by EGb 761 (Figure 4.10). 
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Figure 4.10 EGb 761 rapidly decreases systolic blood pressure in Spargue-Dawley rats via NO release. 
A time course of systolic blood pressure is displayed. Blood pressure is measured via 
catheterization of the carotid artery after i.v. injection of EGb 761 (5 mg/animal) or i.v. 
injection of L-NAME (4 mg/animal) 30 min prior to EGb 761 application. Data are presented 
as mean ± SEM (n=3). *≤0.05 vs. L-NAME/EGb 761 treated animals, Student’s t-test. In Vivo 
Blood Pressure Measurement was kindly performed by Andreas Hartkorn (Ludwig-
Maximilians-University of Munich, Department of Pharmacy – Centre of Drug Research). 
4.1.6 EGb 761 augments eNOS phosphorylation in thoracic aortas 
The observed in vivo effects, regarding EGb 761-induced reduction of blood pressure were 
further confirmed by Western blot analysis. Therefore, Sprague-Dawley rats were treated with 
a bolus injection of EGb 761 (5 mg/animal) and protein samples of lung thoracic aortas were 
gained as described in materials and methods. The results, displayed in Figure 4.11, show a 
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significant increase (> 2-fold) in eNOS phosphorylation at Ser1177 in thoracic aortas obtained 
from EGb 761-treated animals compared to untreated controls. 
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Figure 4.11 EGb 761 induces phosphorylation of eNOS at Ser1177 in rat thoracic aortas. 
Western blot analysis showing phospho-eNOS (Ser1177, upper panel) and total eNOS protein 
levels (lower panel) of thoracic aorta in untreated controls or following EGb 761 treatment 
(5 mg/animal for 5 min). The graph displays the signal intensity obtained by fluorimetric 
evaluation. Bars represent the mean of phospho-eNOS signals normalized to total eNOS 
signals (n=2). Stimulation of Sprague-Dawley rats and isolation of lungs thoracic aortas was 
kindly performed by Andreas Hartkorn (Ludwig-Maximilians-University of Munich, 
Department of Pharmacy – Centre of Drug Research). 
 
 
 
 
 
 
 
 
4  RESULTS 73 
4.2 Angiogenesis 
The onset of angiogenesis, i.e. the “angiogenic switch”, is responsible for tumor progression 
beyond a size of 2 to 3 mm³ as well as for tumor metastasis. Inhibition of angiogenesis, 
therefore, represents a valid approach for cancer treatment or even prevention. Since Ginkgo 
biloba extract is traditionally used for anticancer treatment, we were interested in the anti-
angiogenic effect of EGb 761. Furthermore, we investigated the influence of EGb 761 on 
growth factor-signaling pathways in endothelial cells focusing on the ERK-cascade and the 
role of phosphatases. 
4.2.1 EGb 761 has anti-proliferative properties 
Endothelial cell proliferation is one of the first major steps in angiogenesis. Therefore, the 
effects of EGb 761 on endothelial cell proliferation were assessed using either Crystal Violet 
Staining or direct counting of viable cells. As demonstrated in Figure 4.12, we were able to 
show a dose-dependent reduction of endothelial cell proliferation by EGb 761 
(50 to 500 µg/ml) after 72 h. 
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Figure 4.12 EGb 761 significantly inhibits endothelial cell proliferation after 72 h. 
Crystal Violet Staining Assay: HMECs in a reference plate were stained after 24 h serving as 
baseline (day 0). HMECs in the remaining plates were either kept untreated (control) or 
stimulated with different concentrations of EGb 761 for 72 h. *p≤0.05 vs. control, Kryskal-
Wallis One-Way Analysis of Variance on Ranks followed by Student-Newman-Keuls post-hoc 
test. 
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Furthermore, the direct counting of viable cells revealed that EGb 761 significantly 
diminished endothelial proliferation after 48 h down to 54% (EGb 761 500 µg/ml) in 
comparison to untreated controls (Figure 4.13). 
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Figure 4.13 EGb 761 diminishes endothelial cell proliferation after 48 and 72 h. 
Direct counting of viable cells: Cells were either kept untreated (control) or were stimulated 
with different concentrations of EGb 761 for 48 or 72 h. Data are presented as mean ± SEM of 
3 independent experiments. *p≤0.05 vs. control (72 h), #p≤0.05 vs. control (48 h), Kryskal-
Wallis One-Way Analysis of Variance on Ranks followed by Student-Newman-Keuls post-hoc 
test. 
 
4.2.2 Effects of EGb 761 on cell cycle and apoptosis 
In order to understand the mechanism by which EGb 761 inhibits endothelial cell 
proliferation, we investigated its effect on cell cycle and apoptosis by flow cytometry. The 
cell cycle is a series of events during a cell replication period. It comprises the interphase and 
mitosis. The latter subdivides into G1/G0, S and G2 phase, depending on the DNA amount per 
cell. Characteristic for G1/G0 phase is a single, for G2 phase a double DNA content. Treatment 
of HMECs with increasing concentrations of EGb 761 (50 to 500 µg/ml) resulted in S/G2 cell 
cycle arrest (Figure 4.14). In detail, the number of cells in G1/G0 phase significantly 
decreased, whereas in contrast the number of cells in S and G2 phase clearly increased. 
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Figure 4.14 EGb 761 causes cell cycle arrest in S/G2-phase. 
Proliferating endothelial cells were either kept untreated (control) or were treated with 
increasing amounts of EGb 761 for 48 h. For each stimulation three bars are shown 
corresponding to G1/G0 (black), S (light gray) and G2 (dark gray) phase. Data are presented as 
mean ± SEM of 3 independent experiments. *p≤0.05 vs. control, Kryskal-Wallis One-Way 
Analysis of Variance on Ranks followed by Student-Newman-Keuls post-hoc test. 
Moreover, the effects of EGb 761 referring to an induction of apoptosis were assessed in 
either proliferating or confluent cells. In proliferating cells only the highest concentration of 
EGb 761 (500 µg/ml) enhances apoptosis up to 3.6 fold (Figure 4.15). 
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Figure 4.15 EGb 761 enhances apoptosis in proliferating endothelial cells. 
Proliferating endothelial cells were either left untreated (control) or were exposed to EGb 761 
(50 to 500 µg/ml) for 48 h. Data are presented as mean ± SEM of 3 independent experiments. 
*p≤0.05 vs. control, Kryskal-Wallis One-Way Analysis of Variance on Ranks followed by 
Dunn’s Method. 
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In contrast apoptosis rate is not influenced by EGb 761 in confluent endothelial cells (Figure 
4.16). These findings indicate that the anti-proliferative action of EGb 761 is due to a strong 
anti-proliferative effect, rather than to an induction of apoptosis. 
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Figure 4.16 Effects of EGb 761 on apoptosis in endothelial cells. 
Confluent cells were either left untreated (control) or were exposed to EGb 761 (50 to 
500 µg/ml) for 48 h. Data are presented as mean ± SEM of 3 independent experiments. 
*p≤0.05 vs. control, Kryskal-Wallis One-Way Analysis of Variance on Ranks followed by 
Dunn’s Method. 
 
 
4.2.3 EGb 761 inhibits endothelial cell migration and tube formation 
In addition to endothelial proliferation, cell migration and tube formation are targets for 
intervention in the angiogenesis cascade. Migration of HUVECs, as examined in the wound 
healing assay, was significantly inhibited by EGb 761. In comparison to untreated controls 
(HUVEC growth medium) the percentage of cell-covered area in relation to the total image 
area was reduced to 77% and 72% with EGb 100 and 500 µg/ml, respectively (Figure 4.17 A 
and B). 
Tube formation is a process, which measures the ability of endothelial cells to form three-
dimensional structures. The incubation of HMECs with EGb 761 (100 and 500 µg/ml, 
respectively) on MatrigelTM led to a significant reduction in tube formation (Figure 4.17 C). 
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Figure 4.17 Ginkgo biloba extract abrogates endothelial migration and tube formation. 
A, a confluent HUVEC monolayer was scratched and then exposed to fresh HUVEC growth 
medium (control) or medium containing EGb 761 (100 and 500 µg/ml, respectively) for 16 h. 
One representative image out of 3 independent experiments is shown. B, The graph displays 
the ratio of pixels covered by cells and pixels in the wound area. Data are presented as mean ± 
SEM of 3 independent experiments. *p≤0.05 vs. control, Kryskal-Wallis One-Way Analysis of 
Variance on Ranks followed by Student-Newman-Keuls post-hoc test. C, HMECs were seeded 
on MatrigelTM. Subsequently, cells were either left untreated (control) or were treated with 
EGb 761 (100 and 500 µg/ml, respectively) for 16 h. Representative images out of 3 
independent experiments are shown. 
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4.2.4 EGb 761 abrogates in vivo angiogenesis 
The observed anti-angiogenic properties were confirmed in vivo using the Chicken 
Chorioallantoic Membrane (CAM) Assay. Most importantly, the CAM assay, which is a 
widely used in vivo method, revealed a strong induction of angiogenesis with FGF and an 
inhibition of this effect by EGb 761 showing for the first time an anti-angiogenic effect of 
EGb 761 in vivo (Figure 4.18). 
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Figure 4.18 EGb 761 exerts anti-angiogenic effects in vivo. 
Fertilized eggs were stimulated with either FGF (1 ng/disk) alone or FGF and EGb 761 for 
16 h. The dotted circles indicate the position of the disk carrying the growth factor and 
EGb 761. One representative image of the chicken CAM out of 3 independent experiments is 
shown. The CAM Assay was kindly performed by Johanna Liebl (Ludwig-Maximilians-
University of Munich, Department of Pharmacy – Centre of Drug Research). 
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4.2.5 ERK inhibition exerts anti-angiogenic effects in vitro and in vivo 
Recent studies demonstrate the requirement for the extracellular signal-regulated kinase 
(ERK) on growth factor induced angiogenesis. In order to confirm the influence of ERK on 
angiogenic parameters in our setting, we investigated whether U0126, a specific MEK 1/2 
inhibitor, shows an anti-angiogenic profile. Indeed, U0126 (10 µM, 72 h) inhibits endothelial 
cell proliferation in HMECs by 32% (Figure 4.19). 
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Figure 4.19 ERK inhibition clearly diminishes endothelial cell proliferation. 
Crystal Violet Staining Assay: HMECs in a reference plate were stained after 24 h serving as 
baseline (day 0). HMECs in the remaining plates were either kept untreated (control) or 
stimulated with U0126 (10 µM) for 72 h. Data are presented as mean ± SEM of 3 independent 
experiments. *p≤0.05 vs. control, Kryskal-Wallis One-Way Analysis of Variance on Ranks 
followed by Student-Newman-Keuls post-hoc test. 
 
Furthermore, U0126 (10 µM, 16 h) showed a reduction in both angiogenic parameters: cell 
migration (Figure 4.20 A and B) and tube formation (Figure 4.20 C). In detail, endothelial 
migration expressed as the ratio of pixels covered by cells and the total number of pixels in 
the wound area was diminished to 75% by U0126. Moreover, the two panels in Figure 4.20 C 
clearly illustrate the down-regulation of capillary tubes by U0126 compared with untreated 
controls. 
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Figure 4.20 ERK inhibition reduces endothelial cell migration and tube formation. 
A, Confluent HUVEC monolayers were wounded and stimulated with HUVEC growth 
medium (control) alone or medium containing U0126 (10 µM) for 16 h. One representative 
image out of 3 independent experiments is shown. B The graph displays the ratio of pixels 
covered by cells and pixels in the wound area. Data are presented as mean ± SEM of 3 
independent experiments. *p≤0.05 vs. control, Kryskal-Wallis One-Way Analysis of Variance 
on Ranks followed by Dunn’s Method. C, HMECs were seeded on MatrigelTM. Subsequently, 
cells were incubated with U0126 (10 µM, 16 h). One representative image out of 3 independent 
experiments is shown. 
In addition to these ex vitro experiments, the Chicken Chorioallantoic Membrane (CAM) 
Assay was performed. ERK inhibition by U0126 led to a diminished number of vascular 
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structures in the CAM Assay (Figure 4.21). These data support the hypothesis that ERK 
indeed plays a crucial role in angiogenesis. 
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Figure 4.21 ERK inhibition clearly diminishes the number of vascular structures in the CAM Assay. 
Fertilized eggs were stimulated with either FGF (1 ng/disk) alone or FGF and U0126 for 16 h. 
The dotted circles indicate the position of the disk carrying the growth factor and U0126. One 
representative image of the chicken CAM out of 3 independent experiments is shown. The 
CAM Assay was kindly performed by Johanna Liebl (Ludwig-Maximilians-University of 
Munich, Department of Pharmacy – Centre of Drug Research). 
4.2.6 Effects of EGb 761 on ERK phosphorylation 
As described in the previous section, the mitogen activated protein kinase ERK is crucially 
involved in the angiogenic process. In order to investigate the influence of EGb 761 on ERK 
phosphorylation induced by growth factors, endothelial cells were pre-treated with EGb 761 
(500 µg/ml, 30 min) previous to FGF exposure (5 ng/ml, 30 min). Interestingly, EGb 761 
completely abolished FGF-induced ERK phosphorylation both in HMECs and HUVECs 
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(Figure 4.22 A and B, respectively). Moreover, EGb 761 also suppressed VEGF-induced 
ERK phosphorylation (Figure 4.22 C and D, respectively). 
These results clearly show that EGb 761 abrogates ERK phosphorylation induced by different 
growth factors leading to the suggestion that EGb 761 inhibits angiogenesis via ERK 
inhibition. 
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Figure 4.22 EGb 761 abrogates growth factor-induced ERK phosphorylation in endothelial cells. 
HMECs (A) or HUVECs (B) were pre-treated with EGb 761 (500 µg/ml, 30 min) and 
subsequently exposed to FGF (5 ng/ml, 30 min). HMECs (C) or HUVECs (D) were pre-treated 
with EGb 761 (500 µg/ml, 30 min) before VEGF (50 ng/ml, 10 min) stimulation. Levels of 
phospho-ERK and total ERK protein were determined by Western blot analysis. One 
representative image out of 3 independent experiments is shown. 
4.2.7 EGb 761 short-term treatment exerts anti-proliferative actions 
As revealed in the previous experiment, the inhibitory effect of EGb 761 on growth factor-
induced ERK phosphorylation was observed after only 1 h treatment. In order to analyze if 
short-time stimulation also reveals an anti-proliferative action, a Crystal Violet Staining 
Assay was performed. Importantly, the short-time stimulation with EGb 761 (500 µg/ml, 1 h) 
significantly reduced endothelial proliferation to 74% of untreated controls (Figure 4.23). 
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This anti-proliferative effect was weaker compared to treatment over a period of 72 h (down-
regulation up to 51%). Conclusively, these findings indicate that the anti-proliferative effects 
of EGb 761 are in part exerted by a rapid influence of signaling molecules. 
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Figure 4.23 EGb 761 rapidly inhibits endothelial cell proliferation (≤ 1 h treatment). 
Crystal Violet Staining Assay: HMECs in a reference plate were stained after 24 h serving as 
baseline (day 0). HMECs in the remaining plates were either kept untreated (control) or 
stimulated with EGb 761 (500 µg/ml) for either 1 or 72 h. Following 1 h of incubation, 
supernatants containing EGb 761were removed and cells were refed with HMEC growth 
medium. Data are presented as mean ± SEM of 3 independent experiments. *p≤0.05, Kryskal-
Wallis One-Way Analysis of Variance on Ranks followed by Dunn’s Method. 
4.2.8 Activation of NO/PKG and PI3K/Akt signaling pathways by EGb 761 has no 
influence on the reduction of ERK phosphorylation 
As abovementioned, we have shown that EGb 761 causes an up-regulation and activation of 
eNOS protein in endothelial cells, thus leading to an enhanced production of nitric oxide 
(NO). Furthermore, the phosphorylation of protein kinase B/Akt (Ser473) was found to be 
increased after EGb 761 exposure in EA.hy926 cells. Both signaling pathways, NO/PKG and 
Akt, were communicated to suppress ERK phosphorylation mainly via inhibition of Raf-1. 
Since EGb 761 activates both signaling molecules, the influence of these mediators on the 
reduction of ERK phosphorylation was examined. Neither NO synthase inhibitor L-NAME 
nor PI3K-inhibitor wortmannin affected the inhibitory effect of EGb 761 on ERK 
phosphorylation (Figure 4.24). These results exclude an involvement of either NO/PKG or 
PI3K/Akt pathways on the inhibitory effect on ERK phosphorylation. 
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Figure 4.24 Activation of NO/PKG and PI3K/Akt signaling pathways by EGb 761 did not influence the 
effects on ERK phosphorylation. 
A, HMECs were either left untreated or treated with L-NAME (NOS inhibitor, 100 µM, 
30 min), EGb 761 (500 µg/ml, 30 min) and FGF (5 ng/ml, 30 min) alone or pre-treated with  
L-NAME before EGb 761 and FGF. B, Cells were pre-treated with wortmannin (PI3K 
inhibitor, 50 nM, 30 min) and subsequently exposed to EGb 761 and FGF. Levels of phospho-
ERK (Thr202/Tyr204, upper panel) and total ERK (lower panel) protein were determined by 
Western blot analysis. One representative blot out of 3 independent experiments is shown. 
 
4.2.9 Effects of EGb 761 on cyclic adenosine monophosphate 
Cyclic adenosine monophosphate (cAMP, cyclic AMP or 3'-5'-cyclic adenosine 
monophosphate), derived from adenosine triphosphate (ATP), is an important second 
messenger. cAMP transfers the effects of hormones like glucagon and adrenaline and has an 
impact on intracellular signal transduction. Moreover, cAMP is considered to be a potential 
regulator of ERK inhibition. Since cAMP activates protein kinase A (PKA), which has also 
been shown to inhibit the Raf-MEK-ERK pathway, we examined whether EGb 761 increases 
cAMP levels. Indeed, 30 min of EGb 761 treatment increased intracellular levels of cAMP to 
approximately 1.6-fold (Figure 4.25). 
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Figure 4.25 EGb 761 up-regulates adenylat cyclase activity. 
Adenylate cyclase activity was determined by cAMP radioimmunoassay and measured either 
in absence of any stimulatory agent (control) or in the presence of EGb 761 (500 µg/ml, 
30 min). Data are presented as mean ± SEM of 3 independent experiments. *p≤0.05 vs. 
control, Kryskal-Wallis One-Way Analysis of Variance on Ranks followed by Student-
Newman-Keuls post-hoc test. The second part of this experiment is an enzyme-linked 
immunosorbant assay (ELISA) which was kindly performed by Dr. Hermann Ammer 
(Professor of Clinical Pharmacology, Department of Veterinary Sciences, University of 
Munich). 
In order to verify if these increased cAMP levels are able to influence ERK phosphorylation, 
forskolin as well as 3-isobutyl-1-methylxanthine (IBMX) were used. Forskolin is commonly 
used to raise levels of cAMP in cell physiology assays by resensitizing cell receptors and 
activating the enzyme adenylate cyclase. IMBX is a potent cyclic nucleotide 
phosphodiesterase inhibitor. Due to this action, the compound increases cAMP levels thereby 
activating cAMP-dependent protein kinase A (PKA). Interestingly, enhanced cAMP levels 
caused either by forskolin alone or in combination with IBMX reduced FGF-induced ERK 
phosphorylation in HMECs (Figure 4.26). 
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Figure 4.26 Influence of increased cAMP level on ERK phosphorylation. 
HMECs were pre-treated with either forskolin alone (10 µM, 30 min) or a combination of 
forskolin and IBMX (10 µM, 30 min). Afterwards, cells were stimulated with FGF (5 ng/ml, 
30 min). ERK phosphorylation was investigated by Western blot analysis. One representative 
blot out of two independent experiments is shown. 
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To clarify whether the elevated cAMP levels influence the effect of EGb 761 on ERK 
phosphorylation, cells were pre-treated with two specific inhibitors of PKA, cAMPS-Rp 
(100 µM, 30 min) and PKI (50 µM, 30 min) (Figure 4.27). 
Importantly, the inhibitory effect of EGb 761 on ERK phosphorylation was not influenced by 
cAMP, since inhibition of PKA did not reverse the effect of EGb 761. In summary, these 
results clearly demonstrate that the signaling pathway of cAMP/PKA is not involved in the 
inhibitory effects of EGb 761 on ERK phosphorylation. 
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Figure 4.27 PKA inhibitors do not reverse the decreased ERK phosphorylation by EGb 761. 
A, HMECs were either left untreated or treated with cAMPS-Rp (PKA inhibitor, 100 µM, 
30 min), EGb 761 (500 µg/ml, 30 min) and FGF (5 ng/ml, 30 min) alone or pre-treated with 
cAMPS-Rp before EGb 761 and FGF. B, endothelial cells were pre-treated with PKI (PKA 
inhibitor, 50 µM, 30 min) and subsequently exposed to EGb 761 and FGF. Levels of phospho-
ERK (Thr202/Tyr204, upper panel) and total ERK (lower panel) protein were determined by 
Western blot analysis. One representative blot out of two independent experiments is shown. 
4.2.10 Serine/threonine phosphatase inhibition does not affect the inhibitory effect of 
EGb 761 on ERK phosphorylation 
Protein phosphorylation is regulated by a balance between kinases and phosphatases. The 
latter can be subdivided based upon their substrate specificity into two groups: the 
serine/threonine and tyrosine phosphatases, respectively. In order to investigate an activation 
of phosphatases by EGb 761, phosphatase inhibitors were used. Pre-treatment of HMECs with 
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NaF (serine/threonine phosphatase inhibitor) did not reverse the inhibitory effect of EGb 761 
on ERK phosphorylation (Figure 4.28). 
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Figure 4.28 Influence of the serine/threonine phosphatase inhibitor NaF on the diminished ERK 
phosphorylation by EGb 761. 
HMECs were pre-treated with NaF (1 mM, 30 min). Afterwards, cells were treated with 
EGb 761 (500 µg/ml, 30 min) and FGF (5 ng/ml, 30 min). Levels of phospho-ERK 
(Thr202/Tyr204, upper panel) and total ERK (lower panel) protein were determined. One 
representative blot out of 3 independent experiments is shown. 
In order to verify the lack of effects on serine/threonine phosphatases, a phosphatase assay for 
PP2A, PP2B, and PP2C activities, was performed. Indeed, EGb 761 does not induce, but 
instead clearly inhibits PP2A (Figure 4.29), PP2B, and PP2C activity (Figure 4.30). 
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Figure 4.29 EGb 761 diminishes the activity of PP2A. 
HMECs were either left untreated or treated with NaF (1 mM, 30 min), EGb 761 (500 µg/ml, 
30 min) and FGF (5 ng/ml, 30 min) alone or pre-treated with NaF before EGb 761 and FGF. 
Data are presented as mean ± SEM of 3 independent experiments. *p≤0.05 vs. control, 
Kryskal-Wallis One-Way Analysis of Variance on Ranks followed by Student-Newman-Keuls 
post-hoc test. 
88  4  RESULTS 
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
X
X X
X
NaF
FGF
XEGb 761
PP
2B
 a
ct
iv
ity
(x
-fo
ld
co
nt
ro
l)
*
*
*
0.0
0.2
0.4
0.6
0.8
1.0
1.2
X
X X
X
NaF
FGF
XEGb 761
PP
2C
 a
ct
iv
ity
(x
-fo
ld
co
nt
ro
l) * *
*
A
B
 
 
Figure 4.30 EGb 761 diminishes the activity of PP2B (A) and PP2C (B). 
HMECs were either left untreated or treated with NaF (1 mM, 30 min), EGb 761 (500 µg/ml, 
30 min) and FGF (5 ng/ml, 30 min) alone or pre-treated with NaF before EGb 761 and FGF. 
PP2B and PP2C activity was assessed. Data are presented as mean ± SEM of 3 independent 
experiments. *p≤0.05 vs. control, Kryskal-Wallis One-Way Analysis of Variance on Ranks 
followed by Student-Newman-Keuls post-hoc test. 
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4.2.11 EGb 761 blocks the Raf-MEK-ERK-pathway via activation of tyrosine 
phosphatases 
Stimulation with Na3VO4 (tyrosine phosphatase inhibitor) previous to EGb 761 and FGF 
exposure blocked the effect of Ginkgo biloba extract on ERK inhibition (Figure 4.31). 
Conclusively, EGb 761 abolished growth factor-induced ERK phosphorylation in endothelial 
cells via induction of tyrosine phosphatase activity. 
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Figure 4.31 Pre-treatment with sodium vanadate blocks the inhibitory effect of EGb 761 on ERK 
phosphorylation. 
A, HMECs were pre-treated with Na3VO4 (tyrosine phosphatase inhibitor, 100 µM, 30 min). 
Subsequently, cells were exposed to EGb 761 (500 µg/ml, 30 min) and FGF (5 ng/ml, 30 min). 
B, HMECs were pre-treated with Na3VO4 before EGb 761 and VEGF (50 ng/ml, 10 min). 
Levels of phospho-ERK (Thr202/Tyr204, upper panel) and total ERK (lower panel) protein 
were determined. One representative blot out of 3 (A) and 2 (B) independent experiments is 
shown. 
 
Before we have seen that tyrosine phosphorylation plays a key role in cellular signaling of 
Ginkgo biloba extract. Therefore, overall tyrosine phosphorylation was assessed performing 
Western blot analysis. EGb 761 diminished tyrosine phosphorylation in comparison to 
untreated controls and FGF-stimulated HMECs (Figure 4.32). 
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Figure 4.32 EGb 761 diminishes total tyrosine phosphorylation. 
HMECs were either left untreated or were treated with FGF (5 ng/ml, 30 min) with or without 
pre-treatment with EGb 761 (500 µg/ml, 30 min). Tyrosine phosphorylation was assessed by 
Western blot analysis. Equal protein loading was controlled by staining the membrane with 
Ponceau (a representative fragment of the stained membrane is shown). One representative 
Western blot out of 3 independent experiments is displayed. 
In order to get information on targets of phosphatases in ERK signaling, we examined the 
activation of upstream kinases MEK 1/2 and Raf-1 using Western blot analysis and kinase 
assay, respectively. EGb 761 completely abolished FGF-induced MEK 1/2 phosphorylation at 
Ser217/221 in HUVECs. Moreover, the effect of EGb 761 on MEK 1/2 phosphorylation was 
reversed by pre-incubation with the phosphatase inhibitor sodium vanadate (Figure 4.33). 
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Figure 4.33 Pre-treatment with sodium vanadate reversed the inhibitory effect of EGb 761 on MEK 1/2 
phosphorylation. 
HUVECs were pre-incubated with Na3VO4 (100 µM, 30 min) and afterwards stimulated with 
EGb 761 (500 µg/ml) and FGF (5 ng/ml, 30 min). Levels of phospho-MEK 1/2 (Ser217/221, 
upper panel) protein were determined by Western blot analysis. The bottom panel depicts total 
ERK protein levels as control for equal protein loading. 
Furthermore, we observed a reduction of FGF-induced Raf-1 activity as well as a reduction of 
Raf-1 phosphorylation at Ser338/Tyr341 by EGb 761. Pre-treatment with sodium vanadate 
blocked the inhibitory effect on Raf-1 activation as well as phosphorylation (Figure 4.34). 
These data clearly indicate that Ginkgo biloba extract inhibits growth factor signaling 
upstream of the classical Raf-MEK-ERK pathway. 
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Figure 4.34 The inhibitory effects of EGb 761 on Raf-1 phosphorylation as well as Raf-1 activity were 
reversed by pre-incubation with the tyrosine phosphatase inhibitor sodium vanadate. 
HUVECs were pre-incubated with Na3VO4 (100 µM, 30 min) and afterwards stimulated with 
EGb 761 (500 µg/ml) and FGF (5 ng/ml, 30 min). Representative Western blots are shown for 
phospho-Raf-1 (Ser338/Tyr341) at both high and low intensity. Additionally, Raf kinase 
activity (assessed as phospho-MEK 1/2 using Western blot analysis) was determined. Total 
ERK protein levels served as loading control. 
4.2.12 EGb 761 does not influence PMA-induced ERK phosphorylation 
In order to confirm an involvement of protein tyrosine phosphatases linked to VEGF and FGF 
receptors, cells were treated with EGb 761 and phorbol ester phorbol-12 myristate-13 acetate 
(PMA). PMA leads to growth factor independent activation of the MAPK signaling cascade 
Raf-MEK-ERK. As expected, EGb 761 did not suppress PMA-induced ERK phosphorylation 
(Figure 4.35). These results indicate that EGb 761 terminates ERK phosphorylation by 
activation of one or more tyrosine phosphatases connected with GF receptors, but not by 
influencing the receptor activities themselves. 
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Figure 4.35 PMA-induced ERK phosphorylation was not diminished by EGb 761. 
HMECs were pre-treated with EGb 761 (500 µg/ml, 30 min) and subsequently exposed to 
PMA (50 nM, 10 min). Protein levels of phospho-ERK (Thr202/Tyr204, upper panel) and total 
ERK (lower panel) were determined. All experiments were carried out 3 times with consistent 
results. 
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4.2.13 The anti-angiogenic effect of EGb 761 depends on the activation of protein 
tyrosine phosphatases 
To causally link the activation of tyrosine phosphatases to the anti-angiogenic effects of 
EGb 761, endothelial cell migration was analyzed in the presence of the inhibitor of protein 
tyrosine phosphatases (PTPs) sodium vanadate (Na3VO4).  
Endothelial cells were pre-treated with Na3VO4 (10 µM, 30 min) before exposure to EGb 761 
(100 and 500 µg/ml, respectively) for 16 h. Pre-treatment of endothelial cells with Na3VO4 
reversed the inhibitory effects of EGb 761 on endothelial cell migration. Figure 4.36 displays 
representative images, whereas Figure 4.37 shows the quantification of the experiment. In 
summary, these data provide further evidence that EGb 761 exerts its anti-angiogenic effects 
via an activation of tyrosine phosphatases. 
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Figure 4.36 EGb 761 diminishes HUVEC migration by induction of tyrosine phosphatases. 
The wounded monolayers were refed either with EGb 761 (100 and 500 µg/ml, respectively) or 
Na3VO4 (10 µM) alone for 16 h, or were pre-treated with Na3VO4 (10 µM, 30 min) before 
stimulation with EGb 761 for further 16 h. Representative images out of 3 independent 
experiments are shown. 
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Figure 4.37 EGb 761 diminishes HUVEC migration by induction of tyrosine phosphatases. 
The wounded monolayers were refed either with EGb 761 (100 and 500 µg/ml, respectively) or 
Na3VO4 (10 µM) alone for 16 h, or were pre-treated with Na3VO4 (10 µM, 30 min) before 
stimulation with EGb 761 for further 16 h. Values are expressed as mean ± SEM. *p≤0.05 vs. 
control, #p≤0.05 vs. EGb 761 (100 and 500 µg/ml, respectively), Kryskal-Wallis One-Way 
Analysis of Variance on Ranks followed by Student-Newman-Keuls post-hoc test. 
Moreover, the same stimulation scheme was used to analyze the effects of phosphatase 
inhibition per se on Raf-1 and ERK phosphorylation. Pre-incubation with sodium vanadate 
before exposure to EGb 761 (500 µg/ml, 30 min) revealed a strong increase of both Raf-1 and 
ERK phosphorylation (Figure 4.38). 
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Figure 4.38 Pre-treatment with sodium vanadate before exposure to EGb 761 increases the 
phosphorylation of ERK, Akt and Raf-1. 
HUVECs were pre-treated with different concentrations of Na3VO4 (30 min). Subsequently, 
cells were exposed to EGb 761 (500 µg/ml, 30 min). Levels of phospho-ERK 
(Thr202/Tyr204), phospho-Akt (Ser473) and phospho-Raf (Ser338/Tyr341) protein were 
determined. Total Akt and ERK protein levels served as loading control. One representative 
blot out of 3 independent experiments is shown. 
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4.2.14 Effects of EGb 761 on the phosphatase MKP-1 
Since PTPs were identified as the crucial regulators of the anti-angiogenic action as well as 
the reduced ERK phosphorylation of EGb 761, we were interested which specific phosphatase 
leads to these inhibitory effects. MKP-1 is a dual specificity MAPK phosphatase, which 
inactivates ERK by dephosphorylation of the two critical MAPK residues (Thr202/Tyr204) 
accountable for its activation. MKP-1 mRNA levels, analyzed by Real-time RT-PCR, were  
up-regulated by EGb 761 (500 µg/ml). Interestingly, MKP-1 protein expression, the main 
regulatory parameter for MKP-1 activity, was not affected by EGb 761 (Figure 4.39). Hence, 
MKP-1 is not responsible for the inhibitory effect of EGb 761 on ERK phosphorylation. 
These findings were attributed by the results that growth factor-induced activation of 
MEK 1/2 and even Raf-1 were suppressed by Ginkgo biloba extract (Figure 4.34). 
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Figure 4.39 Effects of EGb 761 on MKP-1. 
A, HMECs were either left untreated (co) or were treated with EGb 761 (500 µg/ml) for 
indicated times. Bars represent mean ± SEM of 3 independent experiments. *p≤0.05 vs. 
control, Kryskal-Wallis One-Way Analysis of Variance on Ranks followed by Student-
Newman-Keuls post-hoc test. B, HUVECs were either left untreated or were stimulated with 
EGb 761 (500 µg/ml) for indicated times. Levels of MKP-1 protein (upper panel) were 
determined. The lower panel depicts the staining with Ponceau as control for equal protein 
loading. One representative image out of 3 independent experiments is shown. 
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4.2.15 EGb 761 inhibits endothelial proliferation via activation of SHP-1 
Another important protein tyrosine phosphatase in FGF and VEGF signaling is the 
cytoplasmic SHP-1. This phosphatase has been shown to interact with FGF and VEGF 
receptors and plays a negative regulatory role in the ERK phosphorylation. To analyze a 
potential involvement of SHP-1 in the inhibitory effects of EGb 761 on ERK phosphorylation, 
we examined whether Ginkgo biloba extract influences SHP-1 activity. Indeed, SHP-1 
activity was clearly induced by EGb 761 (500 µg/ml, 30 min) to approximately 1.5-fold 
(Figure 4.40). 
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Figure 4.40 Induction of SHP-1 activity by EGb 761 may lead to the inhibitory effect on endothelial cell 
proliferation. 
A, HUVECs were either left untreated (control) or were treated with EGb 761 (500 µg/ml) for 
30 min. SHP-1 phosphatase activity was determined as described in Material and Methods 
using pNPP as phosphatase substrate. Bars represent the mean ± SEM of 3 independent 
experiments. *p≤0.05 vs. control, Kryskal-Wallis One-Way Analysis of Variance on Ranks 
followed by Student-Newman-Keuls post-hoc test. 
siRNA experiments were performed to verify whether SHP-1 leads to the reduced endothelial 
proliferation by EGb 761. Indeed, the enhanced growth inhibition in HUVECs transfected 
with siCONTROL non-targeting siRNA by EGb 761 was clearly, but not completely blocked 
in cells lacking SHP-1 (Figure 4.41). In detail, we assessed a growth inhibition of 22% in 
HUVECs transfected with siCONTROL non-targeting siRNA by EGb 761. In contrast, 
growth inhibition was diminished to 12% in cells lacking the PTP SHP-1. Furthermore, 
Figure 4.41 shows the success in silencing SHP-1 by siRNA after 24 and 96 h, respectively. 
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Figure 4.41 SHP-1 is involved in the reduced proliferation by EGb 761. 
A, HUVECs were transfected with SHP-1 and siCONTROL siRNA. After 24 h Crystal Violet 
Staining Assaywas performed. HUVECs in a reference plate were stained after 24 h serving as 
baseline (day 0). HUVECs in the remaining plates were either kept untreated (control) or 
stimulated with EGb 761 (500 µg/ml, 72 h). Data are presented as mean ± SEM of 3 
independent experiments. *p≤0.05 vs. control, Kryskal-Wallis One-Way Analysis of Variance 
on Ranks followed by Dunn’s Method, #p≤0.001 EGb 761 (500 µg/ml) SHP-1 transfected cells 
vs. non-targeting transfected cells, Student’s t-test. B, Transfection control: SHP-1 protein 
levels in cell lysates from SHP-1 and siCONTROL siRNA were assessed. Equal protein 
loading was controlled by staining membranes with Ponceau. One representative image out of 
3 independent experiments is shown. 
 
Summarizing, our data suggest that SHP-1 activation partly explains the inhibitory effect of 
EGb 761 on endothelial proliferation and is crucially involved in anti-angiogenic action of 
Ginkgo biloba extract. Thus, we clearly demonstrate that SHP-1 is one but perhaps not the 
only tyrosine phosphatase that is affected by EGb 761. 
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5.1 Endothelial nitric oxide production 
5.1.1 EGb 761 and cardiovascular diseases 
In recent years, the interest in traditional herbal remedies has grown rapidly in the 
industrialized world. Moreover, herbal remedies are increasingly recognized as a safe and 
effective alternative to modern synthetic drugs. Ginkgo biloba extract is at the forefront of 
herbal remedies and has gained great popularity in European countries and the USA over the 
last decades.133 The epidemiological and economical importance of this medicinal herb is 
further supported by the fact that it has maintained a top selling position since 1995 in the 
USA,134, 135 a market with sales of herbal medicines of $4 billion per year at that time, and 
with an annual growth rate of about 25%.136 The indication for the use of Ginkgo extract, 
which is best documented by clinical trials, is dementia resulting from various origins.137 In 
addition, a second field of application for Ginkgo biloba is represented by diseases that are 
connected to dysregulation of vascular tone and endothelial dysfunction, such as Fontaine’s 
Stage II intermittent claudication (peripheral arterial occlusive disease, pAOD),22, 132, 138 
Raynaud’s disease,139 or tinnitus.23 Furthermore, recent publications revealed an 
atherosclerosis inhibiting effect of EGb 761 in cardiovascular high-risk patients 140, 141 as well 
as an improvement of coronary blood flow in patients with coronary artery disease.142 
Despite its growing popularity and the increasing number of studies supporting the beneficial 
role of Ginkgo biloba extract in the treatment of cardiovascular diseases,21, 23, 139-142 its clinical 
use is still underrepresented due to the lack of knowledge about its cellular and molecular 
mechanisms of action.143 One potential mode of action of Ginkgo biloba extract causing 
improved vascular perfusion is described by a beneficial effect on pathologically altered 
hemorheology due to PAF antagonism.144 However, decrease of blood pressure and increase 
of perfusion after treatment with Ginkgo biloba extracts have also been shown in healthy 
humans with presumably normal hemorheological status.145, 146 Taken together, these facts 
hint towards a second hypothesis that has repeatedly been proposed by the scientific 
community: the modulation of nitric oxide (NO) generation by Ginkgo biloba extracts. 
5.1.2 Long-term influence of EGb 761 on transcriptional regulation of eNOS 
In principle, there are two ways to increase NO production: induction of endothelial nitric 
oxide synthase (eNOS) expression and post-translational activation of eNOS.43, 44, 50 The 
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former is a more sustained process that would afford protracted elevation of NO levels, while 
the latter would lead to more acute effects. The latter includes changes in eNOS translocation, 
phosphorylation, and protein-protein-interactions. Several compounds of biogenic origin can 
only act via one of these ways, while others affect both.147-149 The present study shows that 
EGb 761 can enhance production of NO by both aforementioned ways in vitro as well as in 
vivo at concentrations (100 µg/ml) that are likely to be achieved in blood through the regular 
daily intake of 120 to 240 mg, representing normal dosage for effective therapy.150 
Using both the Luciferase Reporter Gene Assay and Western blot Analysis, we observed an 
increased eNOS promoter activity and an elevated expression of eNOS protein levels 
following long-term stimulation for 48 hours with EGb 761 (100 µg/ml or 500 µg/ml, 
respectively). Interestingly, Cheung et al. could not show any influence of Ginkgo biloba 
extract on the expression of endothelial nitric oxide synthase.151, 152 This study, however, 
utilized ECV 304 as an endothelial-like cell model and the observation time was relatively 
short compared to our settings (only 2 or 4 hours). Moreover, the Cheung experiments were 
performed with a Ginkgo biloba extract, which is not considered to be equivalent to the 
standardized extract EGb 761. Since ECV 304 cells have in the meantime definitely turned 
out to be of epithelial origin, this discrepancy does not come as a surprise. Furthermore, we 
investigated the effects of EGb 761 on NO levels measured by [14C]L-arginine/[14C]L-
citrulline conversion assay. The observed increase in NO production was dose-dependent and 
was corroborated by the in vivo measurements of Shen et al. Using electron spin resonance 
(ESR) spectroscopic analysis during ischemia-reperfusion injury of rat hearts, they found that 
low doses of EGb 761 (0, 25, 50, and 100 mg/kg) increased NO production. However, at 
higher doses (200 mg/kg), EGb 761 appeared to be a scavenger of NO. In addition, an 
increase of eNOS mRNA after treatment with Ginkgo biloba extract has previously been 
shown in rat aortas;153 but data on eNOS protein levels were missing in this publication. One 
crucial problem with increasing eNOS expression seems to be that uncoupling of this enzyme 
may occur,154 leading to an increased production of superoxide. This result was only apparent 
following dramatic upregulation, e.g. by eNOS overexpression (11-fold),154 while moderate 
increases (< 3-fold) as demonstrated in our work with Ginkgo biloba as well as described for 
statins and other compounds does not seem to have any of such adverse effects.147 Along this 
line, excessive production of NO is balanced by radical scavengers, giving rise to EGb 761 
induced cardioprotective properties through the regulation of NO levels. 
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5.1.3 Short-term influence of EGb 761 on eNOS activation and localization 
Along with the long-term influence of EGb 761 on eNOS expression, short-term effects on 
this enzyme as well as effects on blood pressure regulation were investigated. Interestingly, 
EGb 761 caused a marked drop in blood pressure in vivo within minutes, as well as a 
significant relaxation of isolated aortic rings that can not be due to altered eNOS expression. 
Besides, this acute decreased blood pressure, recent studies using either spontaneously 
hypertensive rats (SHR) or deoxycorticosterone acetate (DOCA)-salt hypertensive rats 
demonstrated that a long-term administration of Ginkgo biloba extract attenuated the increase 
in blood pressure.153, 155 Similar observations have previously been made with red wine 
polyphenols,156 however the underlying mechanisms of both systems are still unclear. The 
same applies to Ginkgo biloba extract, where acute vasorelaxant effects have been 
observed.157 An interesting hypothesis has recently been suggested by Dell’Agli et al., 
claiming that the vasorelaxant effect of Ginkgo biloba could be due to PDE-5 inhibition by 
biflavones.158 However, in the special extract used in our experiments, the content of 
biflavones is below 0.1%, which is equivalent to approximately 5 µM, a concentration that 
hardly caused PDE-5 inhibition in the work by Dell’Agli et al. An alternative mechanism, 
implying an increase of endogenous endothelial Ca2+ levels after Ginkgo biloba treatment has 
been hypothesized.157 A causal link to vasodilatation or eNOS activation has not been 
demonstrated yet, nor have further mechanistic insights been gained to date. 
In the present study we investigated the role of the phosphoinositide 3-kinases (PI3K)/Akt 
pathway, since this pathway has been proposed as one of the candidates that are capable of 
activating eNOS directly by phosphorylation at serine 1177 (in human eNOS, equivalent to 
Ser1179 in bovine eNOS).50 Indeed, we provide evidence for a rapid increase of eNOS 
phosphorylation after treatment with EGb 761 that was paralleled by phosphorylation of Akt 
at Ser473. Since this phosphorylation site is a substrate for a kinase complex downstream of 
PI3K (PDK2 or mTOR/rictor), and these responses were abolished by the PI3K inhibitor 
wortmannin, we propose the following signaling cascade: Ginkgo extract causes increase of 
endothelial Ca2+ levels, PI3K is activated, further downstream Akt is phosphorylated and, in 
turn phosphorylates the enzyme eNOS. The same observations have previously been made 
with a constituent of green tea, epigallocatechin-3-gallate (EGCG), and the pharmacological 
active component of ginseng, ginsengoside-Rg1. Both are postulated to rapidly induce NO 
production from eNOS via the non-transcriptional PI3K/Akt pathway.159, 160 In addition to 
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phosphorylation, the localization of eNOS is important for its activity.45 In good accordance, 
we found an increased level of phosphorylated eNOS (Ser1177) located at the plasma 
membrane after stimulation with EGb 761 (100 µg/ml). Since translocation of eNOS to the 
plasma membrane does not depend on phosphorylation,45 and considering that we found an 
accumulation of phosphorylated eNOS, but not of total eNOS protein at the plasma 
membrane, we conclude that this increase results from a translocation of activated Akt to the 
plasma membrane,161 and from subsequent local phosphorylation of eNOS at the plasma 
membrane. This step increases the Ca2+ sensitivity of eNOS at a subcellular compartment, 
where elevated cytoplasmic Ca2+ concentrations naturally occur.47 Interestingly, the higher 
phosphorylation status of eNOS by EGb 761 did not only occur in vitro, but was also seen in 
rat aortic tissue following EGb 761 application in vivo. To the best of our knowledge, this 
work suggests for the first time that there is an influence of EGb 761 on the PI3K-Akt-eNOS 
pathway and the phosphorylation of eNOS at the plasma membrane. Activation of the 
PI3K/Akt pathway is, in addition to its influence on eNOS, a key step for diverse biological 
effects mediating cell proliferation, cell growth, and cell survival.56 Therefore, cellular 
activities brought about by EGb 761-induced Akt activation warrant further investigations. 
In conclusion, our study demonstrates that EGb 761 stimulates eNOS protein up-regulation 
and enzyme activation in endothelial cells, thus leading to an enhanced production of NO. 
Moreover, our results suggest that EGb 761 exhibits dual effects referring to both the 
transcriptional and non-transcriptional modulation of endothelial nitric oxide synthase, 
including protein kinase Akt activation and subsequent eNOS phosphorylation. Keeping in 
mind the artificial character of our in vitro and in vivo experiments and their limited 
transferability to the patient, these basic findings give a first hint to the beneficial 
cardiovascular effects of EGb 761 as a therapeutic agent in conditions associated with 
disturbed NO production. Our work supports Ginkgo biloba on the growing list of herbal 
remedies whose modes of actions have now been partially revealed on a molecular  
level.162, 163 
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5.2 Angiogenesis 
5.2.1 The role of Ginkgo biloba in cancer treatment 
In cancer treatment, the concurrent use of natural health products (NHPs) with conventional 
chemotherapy and radiation has risen in order to inhibit tumor progression and reduce the risk 
of metastasis.164 Consequently, there is an increasing need for understanding the molecular 
mechanisms and signaling pathways underlying these beneficial effects. The following herbs 
are traditionally used for anticancer treatment and are anti-angiogenic through multiple 
interdependent processes that include effects on gene expression, signal processing, and 
enzyme activities: Artemisia annua (Chinese wormwood), Viscum album (European 
mistletoe), Resveratrol and Proanthocyanidin (Grape Seed Extract).165, 166 Another example 
that was recently published, describes the traditional Chinese preparation, Danggui Longhui 
Wan, which exhibits anticancer activity with indirubin as active principle.167 
Among the long list of traditional herbs, the interest in Ginkgo biloba extract has grown 
rapidly in the Western world over the last several decades. Although some studies have 
reported an anticancer (chemo-preventive) effect of EGb 761 in various in vitro and in vivo 
experiments, the actual mechanisms of these effects are still elusive.13 The extract of Ginkgo 
biloba leaves has been shown to inhibit human breast cancer cell proliferation both in vitro 
and in vivo.168 In recent studies the anti-proliferative effect was extended to glioma, 
hepatocellular carcinoma, as well as to ovarian and oral cavity cancer cells suggesting a 
widespread application of EGb 761 for tumor growth control.164, 169-171 Besides its anti-
proliferative properties, Ginkgo biloba induces detoxification enzymes such as cytochrom 
P450 (CYP), glutathione S-transferase and quinine reductase to prevent colon cancer,172 and 
exerts anticlastogenic effects on radiation-exposed chromosomes.173, 174 Furthermore,  
Ye et al. have presented epidemiological data supporting an association between regular use 
of Ginkgo biloba (at least six months continuous) and a decreased risk for ovarian cancer.164 
In brief, Ginkgo biloba extracts are supposed to affect various carcinomas by modulating 
several pathways. Along this line, restriction of tumor growth through the inhibition of 
angiogenesis, serves as one major approach for anticancer therapy and is the subject of the 
current work, providing a rational basis for EGb 761-mediated effects on angiogenic 
parameters in endothelial cells. 
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5.2.2 EGb 761 has anti-angiogenic properties 
The present study shows for the first time an anti-angiogenic profile of EGb 761 (100 µg/ml 
and 500 µg/ml, respectively) in vitro, by inhibition of endothelial cell proliferation, migration, 
and tube formation. Regarding the anti-proliferative effect in endothelial cells, we provide 
valuable insight into the molecular mechanism influenced by EGb 761. We found that Ginkgo 
biloba-treated cells accumulate in S/G2 phase, thereby inhibiting endothelial cell proliferation. 
Through further investigation we determined that EGb 761 does not induce considerable 
apoptotic activity on endothelial cells, as it does not affect confluent endothelial cells, and 
proliferating cells only in the highest concentration of 500 µg/ml. These findings indicate that 
the reduced number of cells is due to a strong anti-proliferative effect, rather than an induction 
of apoptosis. 
Using the chicken chorioallantoic membrane (CAM) assay, the in vivo anti-angiogenic 
activity of EGb 761 was demonstrated. These findings corroborate the first hints describing 
that administration of EGb 761 to tumor-bearing mice blocked lymphocyte-induced 
angiogenesis and intraperitoneal administration of a Ginkgo biloba extract inhibited 
neovascularisation in experimental retinopathy of prematurity.175, 176 The results of  
Monte et al., restricted to lymphocyte-induced angiogenesis, suggest a mechanism involving 
the known free radical scavenging activity of Ginkgo biloba extract, whereas the results of 
Juarez et al. revealed a decreased content of growth factors in retinal and vitreous tissues of 
rats or mice. In the present study we propose a new hypothesis that the inhibition of 
angiogenesis by EGb 761 is mediated via ERK inhibition and we provide information 
supporting the molecular mechanism. 
5.2.3 EGb 761 reduces growth factor-induced ERK phosphorylation 
The Raf-MEK-ERK pathway which is activated through growth factors including FGF and 
VEGF is of particular relevance to angiogenesis.74 This pathway has repeatedly been shown 
to be essential for proliferation and cell cycle progression.177 It also protects cells from 
apoptosis and is involved in extracellular matrix (ECM) degradation, endothelial cell 
migration as well as differentiation.63, 178 Accordingly, we found that blockade of ERK 
activation by U0126, a specific MEK 1/2 inhibitor, attenuates endothelial angiogenesis 
including proliferation, migration, and tube formation. Furthermore, we have demonstrated 
that U0126 reversed the number of vascular structures induced by FGF in vivo. The results 
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obtained with U0126 referring to the different angiogenic parameters are comparable with 
these of EGb 761. Moreover, the results point to the involvement of ERK in the anti-
angiogenic properties of EGb 761. The present study shows that EGb 761 (500 µg/ml) 
reduces ERK phosphorylation induced by the growth factors VEGF and FGF in an 
endothelial cell model. Our findings are supported by recently published in vitro studies 
showing that Ginkgo biloba extract inhibits lipopolysaccharid (LPS)-induced phosphorylation 
of ERK in vascular smooth muscle cells and macrophages, respectively.179, 180 
As aforementioned, the activation of ERK is regulated by a three step signaling module, 
comprised of the upstream MAPK kinase kinase Raf-1 and MAPK kinase MEK 1/2.64, 65 The 
pathway can be negatively modulated by various mechanisms at almost every point of the 
Ras-Raf-MEK-ERK cascade. This inhibition of ERK phosphorylation is achieved either by 
blockage of the upstream kinases or activation of phosphatases. Activation i.e. 
phosphorylation of the upstream kinases MEK 1/2 and Raf-1 have been found to be abrogated 
by EGb 761 after short-term treatment in endothelial cells. Finally the question arose, by 
which mechanism these upstream kinases are inhibited. As shown in section 5.1 and recently 
published, EGb 761 activates the signaling cascades of NO/cGMP as well as PI3K/Akt.26 
Both cascades lead to an inhibition of the serine/threonine kinase Raf-1 via phosphorylation at 
Ser259, which keeps the kinase in an auto-inhibited state.69, 70, 181, 182 Therefore, the 
involvement of NO/cGMP as well as PI3K/Akt referring the reduced ERK phosphorylation 
was investigated using specific inhibitors. However, none of these cascades appeared to be 
involved in the inhibitory effect of EGb 761 on ERK phosphorylation. 
Moreover, the present work revealed that EGb 761 clearly enhanced cAMP level. Our finding 
is supported by recently published in vivo studies demonstrating that the concentration of 
cAMP was augmented by 37.5±9.1% (p<0.0078) in the blood of cardiovascular high-risk 
patients after a 2-month therapy with Ginkgo biloba extract.141 The vasodilating second 
messenger cAMP activates the protein kinase A (PKA), which has also been shown to 
phosphorylate Raf-1 at Ser259, thereby inactivating the Raf-MEK-ERK pathway.183 The 
involvement of elevated cAMP/PKA level on the reduced ERK phosphorylation by EGb 761 
could be excluded using two specific inhibitors of PKA, the major effector of cAMP. 
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5.2.4 EGb 761 reduces ERK phosphorylation via induction of tyrosine phosphatases 
Interestingly, nothing has as yet been investigated regarding the potency of EGb 761 to 
influence phosphatases. Therefore, it is of special interest that our results show an activation 
of protein tyrosine phosphatases by EGb 761. On the one hand, protein tyrosine phosphatases 
(PTPs) were identified as the crucial regulator of the reduced ERK phosphorylation and were 
causally linked with the anti-angiogenic effect of EGb 761. On the other hand, an 
involvement of serine/threonine phosphatases on the inhibitory effect of ERK 
phosphorylation by EGb 761 could be excluded. Furthermore, using a specific phosphatase 
assay, a diminished activity of the serine/threonine phosphatases PP2A, PP2B, and PP2C by 
EGb 761 (500 µg/ml) treatment alone or subsequent exposure to EGb 761 and FGF was 
obtained. Comparing to control experiments, following FGF treatment no increase in activity 
was detectable for any of the three phosphatases. However, Lao et al. working with 10-fold 
higher concentrations of FGF (50 ng/ml) and human embryonic kidney cells HEK293T 
revealed a marginal increase in PP2A activity after 30 min and a significant increase after 2 h 
treatment.184 The diminished activity of the phosphatase PP2A confirms the inhibitory effect 
of EGb 761 on ERK phosphorylation since the activity of this phosphatase is required for 
Raf-1 activation, an upstream kinase of ERK. 
Recently, evidence has been given that PTPs function as tumor suppressors and that 
deregulation of PTP function is associated with tumorigenesis in different types of human 
cancinoma.185 Furthermore, individual PTPs exert an antagonistic role in growth factor 
signaling either by direct dephosphorylation of receptor-tyrosine kinases or by 
dephosphorylation of a member of the MAP kinase cascade. Regarding the ERK-cascade, the 
following PTPs have been discussed: MKP-1, LAR, SHP-1, DEP1, PTP1B and HC PTP-A. 
MKP-1 is a dual specificity MAPK phosphatase, which inactivates ERK by 
dephosphorylation of the two critical MAPK residues (Thr202/Tyr204) accountable for its 
activation. MKP-1 is mainly regulated via protein expression, which has not been seen to be 
affected by EGb 761 as determined by Western blot analysis. As we learned that EGb 761 
activates phosphatases upstream of the MAPK cascade, we now focused on PTPs which act 
as direct antagonists of receptor-tyrosine kinases via dephosphorylation of tyrosine residues. 
The hypothesis that EGb 761 terminates ERK phosphorylation by activation of one or more 
tyrosine phosphatases connected with either VEGF or FGF receptors was confirmed by 
experiments using PMA as a substrate. PMA leads to a growth factor independent ERK 
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phosphorylation, which was not inhibited by EGb 761. One example of PTPs, which 
antagonizes receptor-tyrosine kinases, is the src homology-2 (SH2) domain-containing 
phosphatase SHP-1, which is a cytoplasmic PTP. 
SHP-1 was identified to play a largely negative role by suppressing cellular proliferation and 
angiogenesis through growth factors including FGF and VEGF via direct dephosphorylation 
of their receptors. Therefore, we hypothesized that EGb 761 acts directly on SHP-1. In a 
tyrosine phosphatase activity assay, SHP-1 was demonstrated to be rapidly activated by 
EGb 761 (500 µg/ml) within 30 minutes. Furthermore, by using SHP-1 targeting siRNA we 
could confirm the role of SHP-1 activation in suppression of endothelial proliferation by 
Ginkgo biloba extract. Thus, SHP-1 has been identified to be one of the target molecules for 
Ginkgo biloba extract conferring its anti-angiogenic activity. 
In conclusion, EGb 761 exerts anti-angiogenic effects and activates protein tyrosine 
phosphatases (SHP-1 among others) resulting in an inhibition of the Raf-MEK-ERK-pathway. 
These findings provide a rational basis for the chemo-preventive and anticancer effects of the 
herbal remedy EGb 761. The present study adds Ginkgo biloba to the growing list of herbal 
remedies with a rational, mechanistic molecular background. 
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6.1 Endothelial nitric oxide production 
The standardized Ginkgo biloba extract, EGb 761, has been repeatedly proven to be beneficial 
for the prevention and treatment of cardiovascular diseases. In the present work we revealed 
the underlying signaling pathway and the molecular basis on which EGb 761 protects 
endothelial dysfunction both in vitro and in vivo. 
Application of therapeutically feasible doses of EGb 761 for 48 hours caused endothelial 
nitric oxide (NO) production by increasing endothelial nitric oxide synthase (eNOS) promoter 
activity, eNOS protein expression, and eNOS activity ([14C]L-arginine/[14C]L-citrulline 
conversion) in vitro. In addition to these transcriptional effects on eNOS, phosphorylation of 
the enzyme at a site typical for the protein kinase B/Akt (Ser1177) was acutely enhanced by 
treatment with EGb 761, as was Akt phosphorylation at Ser473. Furthermore, the Ginkgo 
biloba extract caused an acute relaxation of isolated rat aortic rings and NO-dependent 
reduction of blood pressure in Sprague-Dawley rats in vivo. 
In summary, our work provides insights into the mechanism by which EGb 761 exerts 
beneficial effects on cardiovascular diseases and shows that EGb 761 enhances endothelial 
NO production by increasing eNOS expression and PI3K/Akt-driven activity of eNOS. These 
influences on eNOS represent a putative molecular basis for the protective cardiovascular 
properties of EGb 761. 
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Figure 6.1 Schematic diagram of the signal transduction pathway of EGb 761 leading to endothelial nitric 
oxide (NO) production and vasodilation. 
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6.2 Angiogenesis 
Ginkgo biloba is traditionally used for anticancer treatment. However, as seen with most of 
the widely used herbal remedies, no profound mechanistic studies providing a rational basis 
for the respective therapeutic indication exist. 
The present study shows an anti-angiogenic profile in vitro of the standardized Ginkgo biloba 
extract EGb 761. The extract inhibits endothelial proliferation, migration and tube formation 
of primary human endothelial cells. Moreover, using the chicken chorioallantoic membrane 
assay (CAM) in vivo anti-angiogenic activity of EGb 761 was demonstrated. During analysis 
of the underlying molecular mechanisms, a significant inhibition of growth factor-induced 
ERK phosphorylation by EGb 761 became evident. Interestingly, inhibitory effects of 
EGb 761 on ERK as well as on upstream kinases MEK 1/2 and Raf-1 could be completely 
reversed by pre-treatment with sodium vanadate, an inhibitor of tyrosine phosphatases. 
Sodium vanadate was able to reverse the EGb 761-induced inhibition of endothelial cell 
migration, an important parameter for angiogenesis. Focusing on tyrosine  
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Figure 6.2 Schematic representation of the molecular mechanism underlying the anti-angiogenic 
properties of EGb 761. 
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phosphatases upstream of the Raf-MEK-ERK cascade, we identified the tyrosine phosphatase 
SHP-1 as a target of EGb 761. SHP-1 was rapidly activated by EGb 761 and silencing SHP-1 
(siRNA experiments) abrogated the EGb 761 evoked reduction of endothelial proliferation. 
In summary, our work provides insights into the mechanism by which EGb 761 has anti-
angiogenic properties and shows that EGb 761 activates protein tyrosine phosphatases leading 
to an inhibition of the Raf-MEK-ERK pathway. This work provides a rational basis for the 
use of the widely consumed herbal remedy Ginkgo biloba in anti-angiogenesis based tumor 
prevention and therapy. 
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8.1 mRNA sequences for Real-time RT-PCR analysis 
Below the mRNA sequences of the human Dual specificity phosphatase 1 (DUSP1), also 
denoted as MKP-1, and the Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are 
displayed. For both sequences forward as well as reverse primers (light blue) and the TaqMan 
probes (light gray) are highlighted. 
 
DEFINITION: Dual specificity phosphatase 1 (DUSP1), mRNA. 
ACCESSION: NM_004417 
SOURCE:  Homo sapiens (human) 
 
        1 tcgctgcgaa ggacatttgg gctgtgtgtg cgacgcgggt cggaggggca gtcgggggaa 
       61 ccgcgaagaa gccgaggagc ccggagcccc gcgtgacgct cctctctcag tccaaaagcg 
      121 gcttttggtt cggcgcagag agacccgggg gtctagcttt tcctcgaaaa gcgccgccct 
      181 gcccttggcc ccgagaacag acaaagagca ccgcagggcc gatcacgctg ggggcgctga 
      241 ggccggccat ggtcatggaa gtgggcaccc tggacgctgg aggcctgcgg gcgctgctgg 
      301 gggagcgagc ggcgcaatgc ctgctgctgg actgccgctc cttcttcgct ttcaacgccg 
      361 gccacatcgc cggctctgtc aacgtgcgct tcagcaccat cgtgcggcgc cgggccaagg 
      421 gcgccatggg cctggagcac atcgtgccca acgccgagct ccgcggccgc ctgctggccg 
      481 gcgcctacca cgccgtggtg ttgctggacg agcgcagcgc cgccctggac ggcgccaagc 
      541 gcgacggcac cctggccctg gcggccggcg cgctctgccg cgaggcgcgc gccgcgcaag 
      601 tcttcttcct caaaggagga tacgaagcgt tttcggcttc ctgcccggag ctgtgcagca 
      661 aacagtcgac ccccatgggg ctcagccttc ccctgagtac tagcgtccct gacagcgcgg 
      721 aatctgggtg cagttcctgc agtaccccac tctacgatca gggtggcccg gtggaaatcc 
      781 tgccctttct gtacctgggc agtgcgtatc acgcttcccg caaggacatg ctggatgcct 
      841 tgggcataac tgccttgatc aacgtctcag ccaattgtcc caaccatttt gagggtcact 
      901 accagtacaa gagcatccct gtggaggaca accacaaggc agacatcagc tcctggttca 
      961 acgaggccat tgacttcata gactccatca agaatgctgg aggaagggtg tttgtccact 
     1021 gccaggcagg catttcccgg tcagccacca tctgccttgc ttaccttatg aggactaatc 
     1081 gagtcaagct ggacgaggcc tttgagtttg tgaagcagag gcgaagcatc atctctccca 
     1141 acttcagctt catgggccag ctgctgcagt ttgagtccca ggtgctggct ccgcactgtt 
     1201 cggcagaggc tgggagcccc gccatggctg tgctcgaccg aggcacctcc accaccaccg 
     1261 tgttcaactt ccccgtctcc atccctgtcc actccacgaa cagtgcgctg agctaccttc 
     1321 agagccccat tacgacctct cccagctgct gaaaggccac gggaggtgag gctcttcaca 
     1381 tcccattggg actccatgct ccttgagagg agaaatgcaa taactctggg aggggctcga 
     1441 gagggctggt ccttatttat ttaacttcac ccgagttcct ctgggtttct aagcagttat 
     1501 ggtgatgact tagcgtcaag acatttgctg aactcagcac attcgggacc aatatatagt 
     1561 gggtacatca agtccatctg acaaaatggg gcagaagaga aaggactcag tgtgtgatcc 
     1621 ggtttctttt tgctcgcccc tgttttttgt agaatctctt catgcttgac atacctacca 
     1681 gtattattcc cgacgacaca tatacatatg agaatatacc ttatttattt ttgtgtaggt 
     1741 gtctgccttc acaaatgtca ttgtctactc ctagaagaac caaatacctc aatttttgtt 
     1801 tttgagtact gtactatcct gtaaatatat cttaagcagg tttgttttca gcactgatgg 
     1861 aaaataccag tgttgggttt ttttttagtt gccaacagtt gtatgtttgc tgattattta 
     1921 tgacctgaaa taatatattt cttcttctaa gaagacattt tgttacataa ggatgacttt 
     1981 tttatacaat ggaataaatt atggcatttc tattg 
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DEFINITION: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), mRNA. 
ACCESSION: NM_002046 
SOURCE:  Homo sapiens (human) 
 
        1 aaattgagcc cgcagcctcc cgcttcgctc tctgctcctc ctgttcgaca gtcagccgca 
       61 tcttcttttg cgtcgccagc cgagccacat cgctcagaca ccatggggaa ggtgaaggtc 
      121 ggagtcaacg gatttggtcg tattgggcgc ctggtcacca gggctgcttt taactctggt 
      181 aaagtggata ttgttgccat caatgacccc ttcattgacc tcaactacat ggtttacatg 
      241 ttccaatatg attccaccca tggcaaattc catggcaccg tcaaggctga gaacgggaag 
      301 cttgtcatca atggaaatcc catcaccatc ttccaggagc gagatccctc caaaatcaag 
      361 tggggcgatg ctggcgctga gtacgtcgtg gagtccactg gcgtcttcac caccatggag 
      421 aaggctgggg ctcatttgca ggggggagcc aaaagggtca tcatctctgc cccctctgct 
      481 gatgccccca tgttcgtcat gggtgtgaac catgagaagt atgacaacag cctcaagatc 
      541 atcagcaatg cctcctgcac caccaactgc ttagcacccc tggccaaggt catccatgac 
      601 aactttggta tcgtggaagg actcatgacc acagtccatg ccatcactgc cacccagaag 
      661 actgtggatg gcccctccgg gaaactgtgg cgtgatggcc gcggggctct ccagaacatc 
      721 atccctgcct ctactggcgc tgccaaggct gtgggcaagg tcatccctga gctgaacggg 
      781 aagctcactg gcatggcctt ccgtgtcccc actgccaacg tgtcagtggt ggacctgacc 
      841 tgccgtctag aaaaacctgc caaatatgat gacatcaaga aggtggtgaa gcaggcgtcg 
      901 gagggccccc tcaagggcat cctgggctac actgagcacc aggtggtctc ctctgacttc 
      961 aacagcgaca cccactcctc cacctttgac gctggggctg gcattgccct caacgaccac 
     1021 tttgtcaagc tcatttcctg gtatgacaac gaatttggct acagcaacag ggtggtggac 
     1081 ctcatggccc acatggcctc caaggagtaa gacccctgga ccaccagccc cagcaagagc 
     1141 acaagaggaa gagagagacc ctcactgctg gggagtccct gccacactca gtcccccacc 
     1201 acactgaatc tcccctcctc acagttgcca tgtagacccc ttgaagaggg gaggggccta 
     1261 gggagccgca ccttgtcatg taccatcaat aaagtaccct gtgctcaacc 
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8.2 Abbreviations 
ACh  acetylcholine 
Akt  proteinkinase B 
APS  ammonium persulfate 
ATP  adenosine5’-triphosphate 
BSA  bovine serum albumin 
CAM  chicken chorioallantoic membrane 
cAMP  cyclic adenosine monophosphate 
cAMPS-Rp (R)-adenosine, cyclic 3',5'-(hydrogenphosphorothioate) 
CAPS  cyclohexylamino-1-propane sulfonic acid 
CCD  charge-coupled device 
cDNA  complementary DNA 
cGMP  cyclic guanosine monophosphate 
CLSM  confocal laser scanning microscopy 
DMEM Dulbecco's Modified Eagle's Medium 
DMSO dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DTT  dithiothreitol 
ECGM Endothelial Cell Growth Medium 
ECL  enhanced chemoluminescence 
ECs  endothelial cells 
EDTA  ethylenediaminetetraacetic acid 
EGb  Extract of Ginkgo biloba 
EGTA  ethylene glycol tetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
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eNOS  endothelial nitric oxide synthase 
ERK  extracellular signal-regulated kinase 
FACS  fluorescence activated cell sorter 
FAM  6-carboxyfluorescein 
FBS  fetal bovine serum 
FGF  fibroblast growth factor 
FL2-H  fluorescent channel 2 height 
FSC  forward scatter 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GF  growth factor 
h  hour 
HEPES N-(2-Hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
HFS  hypotonic fluorochrome solution 
HMEC human microvascular endothelial cell 
HRP  horseradish peroxidase 
HSP  heat shock protein 
HUVEC human umbilical vein endothelial cell 
IBMX  3-isobutyl-1-methylxanthine 
JNK  c-Jun amino-terminal kinases 
kDa  kilo Dalton 
L-NAME L-nitro-arginine-methyl ester 
LPS  lipopolysaccharide 
MAPK mitogen-activated protein kinase 
MAPKK mitogen-activated protein kinase kinase 
MAPKKK mitogen-activated protein kinase kinase kinase 
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MEK  MAPK/ERK kinases 
MKP-1 mitogen-activated protein kinase phosphatases-1 
min  minute 
MOPS  3-(N-morpholino)propanesulfonic acid 
mRNA messenger RNA 
NO  nitric oxide 
NOS  nitric oxide synthase 
PAA  polyacrylamide 
PAGE  polyacrylamide gel electrophoresis 
Pap  papaverine 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PE  phenylephrine 
PI  propidium iodide 
PI3K  phosphoinositide 3-kinase 
PKA  protein kinase A 
PKI  protein kinase A inhibitor 
PMA  phorbol 12-myristate 13-acetate 
PMSF  phenylmethylsulphonyl fluoride 
p-NPP  para-Nitrophenyl phosphate 
PP  protein serine/threonine phosphatase 
PTP  protein tyrosine phosphatase 
PVDF  polyvinylidene fluoride 
RNA  ribonucleic acid 
RNAse ribonuclease 
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ROS  reactive oxygen species 
sGC  soluble guanylate cyclase 
SDS  sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM  standard error of the mean value 
Ser  serine 
SHP-1  src-homology 2 (SH2) domain containing phosphatase 
TAMRA tetramethyl-6-carboxyrhodamine 
TBE  tris, borate, EDTA buffer 
TE  tris-EDTA buffer 
TEMED N, N, N’, N’ tetramethylethylene diamine 
Thr  threonine 
TNF-α  tumor necrosis factor-α 
Tris  trishydroxymethylaminomethane 
Tyr  tyrosine 
VEGF  vascular endothelial growth factor 
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8.3 Alphabetical List of Companies 
Agfa-Gevaert AG    Cologne, Germany 
Alexis Biochemicals    San Diego, CA, USA 
Amaxa     Cologne, Germany 
Amersham Biosciences   Freiburg, Germany 
Applichem     Darmstadt, Germany 
Applied Biosystems    Foster City, CA, USA 
B. Braun Biotech International  Melsungen, Germany 
BD Biosciences    Heidelberg, Germany 
Beckman Coulter    Krefeld, Germany 
Berthold Technologies   Bad Wildbad, Germany 
BIOCHROME AG    Berlin, Germany 
Biomers.net     Ulm, Germany 
Bio-Rad     Munich, Germany 
Biotrend Chemikalien GmbH  Cologne, Germany 
Biozol      Eching, Germany 
Cambrex     Verviers, Belgum 
Cayman Chemical Company   Michigan, USA  
Cell Signalling/New England Biolabs Frankfurt/Main, Germany 
Charles River Wiga GmbH   Sulzfeld, Germany 
Dharmacon     Lafayette, CO, USA 
Dianova     Hamburg, Germany 
Fermentas     St. Leon-Rot, Germany 
Fuji      Düsseldorf, Germany 
Gibco/Invitrogen    Karlsruhe, Germany 
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Hugo Sachs     Hugstetten, Germany 
ibidi GmbH     Munich, Germany 
ICN Biomedicals    Aurora, Ohio, USA 
Interdim     Montulocon, France 
Kodak      Rochester, USA  
Li-Cor Biosciences    Lincoln, NE 
Lohmann Tierzucht    Cuxhaven, Germany 
Macherey-Nagel    Düren, Germany 
Merck      Darmstadt, Germany 
Millipore     Bedford, MA, USA 
Miltenyi Biotec    Bergisch Gladbach, Germany 
Minerva Biolabs    Berlin, Germany 
Molecular Probes/Invitrogen   Karlsruhe, Germany 
NanoDrop     Wilmington, DE, USA 
Olympus     Munich, Germany 
PAA Laboratories    Cölbe, Germany 
PAN Biotech     Aidenbach, Germany 
PeproTech     Rocky Hill, NY, USA 
Peqlab Biotechnologie GmbH  Erlangen Germany 
Perkin Elmer     Massachusetts, USA 
Peske      Aindling-Arnhofen, Germany 
Promega     Mannheim, Germany 
Provitro     Berlin, Germany 
Qiagen GmbH     Hilden, Germany 
Roche      Mannheim, Germany 
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Rockland Immunochemicals   Gilbertsville, Pennsylvania, USA 
SantaCruz Biotechnology   Heidelber, Germany 
S.CO LifeScience    Garching, Germany 
Sigma      Taufkirchen, Germany 
TECAN     Crailsheim, Germany 
TILL Photonics    Gräfelfing, Germany 
Tocris      MO, USA 
TPP      Trasadingen, Switzerland 
Upstate     Lake Placid, NY, USA 
Whatman Schleicher & Schüll  Dassel, Germany  
Zeiss      Oberkochen, Germany 
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8.4 Publications 
8.4.1 Original Publication 
Ginkgo biloba extract EGb 761 increases endothelial nitric oxide production in vitro and in 
vivo. 
A. Koltermann a, A. Hartkorn a, E. Koch b, R. Fürst a, A.M. Vollmar a and S. Zahler a  
a Department of Pharmacy, Pharmaceutical Biology, University of Munich, Germany   
b Preclinical Research, Dr. Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany   
Cell Mol Life Sci. 2007 Jul;64(13):1715-22. 
 
Ginkgo biloba extract EGb 761 exerts anti-angiogenic properties via activation of tyrosine 
phosphatases 
Anja Koltermann a; Johanna Liebl a; Robert Fürst, PhD a; Hermann Ammer, PhD b; Angelika 
M. Vollmar, PhD a; Stefan Zahler, PhD a  
a Department of Pharmacy, Pharmaceutical Biology, University of Munich, Germany   
b Institute of Pharmacology, Toxicology and Pharmacy, University of Munich, Germany 
Submitted 
 
8.4.2 Oral Communication 
Ginkgo biloba extract (EGb 761) inhibits endothelial cell proliferation in vitro.  
Frühjahrstagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie 
und Toxikologie (DGPT); March 13-15th, 2007, Mainz, Germany. 
 
Ginkgo biloba extract (EGb 761) exerts anti-angiogenic properties via activation of tyrosine 
phosphatases. 
Symposium des Graduiertenkollegs (GRK) 438, November 10-11th, 2007, Herrsching, 
Germany. 
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8.4.3 Poster presentations 
Anti-proliferative effects of the Ginkgo biloba extract (EGb 761) on endothelial cells in vitro. 
Koltermann A, Zahler S., Vollmar AM.  
Frühjahrstagung der Deutschen Pharmazeutischen Gesellschaft (PPhG), October 5-8th, 2005, 
Mainz, Germany. 
 
Ginkgo biloba extract (EGb 761) induces the endothelial nitric oxide system.  
Koltermann A, Vollmar AM., Zahler S.  
Frühjahrstagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie 
und Toxikologie (DGPT), April 4-6th, 2006, Mainz, Germany. 
 
Ginkgo biloba extract (EGb 761) increases endothelial NO production in vitro and in vivo. 
Koltermann A, Hartkorn A, Koch E, Fürst R, Vollmar AM, Zahler S.  
Annual Meeting 2006, Gesellschaft für Microzirkulation und Vaskuläre Biologie e.V., 
October 12-14th, 2006, Munich, Germany. 
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8.5 Curriculum vitae 
Persönliche Angaben 
Name:    Anja Koltermann  
Geburtsdatum:   17.04.1977  
Geburtsort:    Elsterwerda  
Familienstand:  ledig 
 
Hochschule: 
08/2004 - 12/2007 Dissertation am Lehrstuhl für Pharmazeutische Biologie    
Department Pharmazie der LMU München   
Betreuer: Prof. Dr. A.M. Vollmar, PD Dr. S. Zahler 
 
08/2004-11/2007  Mitglied des Graduiertenkolleg GRK 438  
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04/1999 - 05/2003 Studium der Pharmazie   
an der TU Carolo-Wilhelmina zu Braunschweig 
 
03/2001   Abschluss des Grundstudiums  
    1. Abschnitt der Pharmazeutischen Prüfung 
 
05/2003   Abschluss des Hauptstudiums  
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    Erlangung der Approbation zur Apothekerin 
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Erlaubnis zur Führung der Berufsbezeichnung:  
Pharmazeutisch-technische Assistentin 
 
1991-1996   Elsterschlossgymnasium in Elsterwerda  
    Abschluss: Allgemeine Hochschulreife 
 
Berufsausbildung und Tätigkeiten 
seit 12/2004 promotionsbegleitende Tätigkeit als Apothekerin  
Apotheke am Kufsteiner Platz und Arcis-Apotheke in München 
 
06/2003-06/2004 Pharmaziepraktikum  
1. Halbjahr: AstraZeneca GmbH in Plankstadt  
Unternehmensbereich: 
- Qualitätssicherung:  
- Pharmafertigung/Verfahrenssicherung   
2. Halbjahr: Arcis-Apotheke in München 
 
1999-2002 studiumsbegleitende Tätigkeit als PTA   
Arnika-Apotheke in München, Kur-Apotheke bei Bad Harzburg, 
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09/1998-02/1999 Berufspraktikum  
Aesculap-Apotheke in Dresden 
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